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Stroke is a major cause of mortality and the leading cause of long-term
disability in the US. More than 60% of individuals suffering a first time stroke develop
respiratory dysfunction, prolonging recovery and increasing mortality. Post-stroke
cognitive decline is a major contributor to disability and nursing home placement,
therefore the cognitive consequences of Stroke Induced Respiratory Dysfunction
(SIRD) need to be explored if we hope to enhance functional recovery. The first step
towards treatment of the negative consequences of SIRD is the development of
appropriate animal models that will allow us to explore the pathophysiology of SIRD
and provide the opportunity to test potential pharmacological agents.
We developed and characterized an animal model of stroke induced
respiratory dysfunction recapitulating the respiratory phenotype witnessed in the
clinical population, characterized by incidences of apnea and hypoventilation.
Interestingly, mice with high incidence of apneas display signs of progressive
cognitive decline compared to those with low/no incidence of apneas. Histological
analysis of vital brainstem respiratory control sites unveiled reactive astrocytosis, an
important cell type in the neurovascular unit and an essential component of
chemoreception. Respiratory dysfunction and brainstem astrocytosis was
reproduced in mice that underwent intracerebroventricular injections of TGF-β.
Suggesting the TGF-β signaling pathway contributes to the onset of astrogliosis and
respiratory dysfunction.
Our data suggests that stroke disrupts basal breathing rather than increasing
chemoreceptor gain. Therefore, we predict treatments designed to stimulate
breathing independent of chemoreceptor gain will improve respiratory instability,
behavior, cognition and mortality. Systemic application of acetazolamide eliminated
apneas while preventing further cognitive decline.
This work not only developed a model of stroke induced respiratory
dysfunction that recapitulates the respiratory phenotype witnessed in the clinical
population, but also providing translational relevance to the field of stroke, aging,
and cognitive decline. Successful treatment of SIRD may lead to significant
improvements in post-stroke recovery and cognition.
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Chapter 1. Introduction.

1.1. Stroke is a leading cause of adult disability:
Stroke continues to be the leading cause of serious long-term disability in the
United States. (1) In 2012, stroke care cost an astounding 77.1 billion dollars, and
due to the aging of the US population, this number is expected to triple by 2030 to
183 billion. Over 4% of the US population has suffered a stroke. (2) This public
health issue is not just faced by the United States; globally stroke is the second
leading cause of death behind ischemic heart disease. (3) Stroke results from the
lack of blood supply (ischemia) to the brain due to a thrombus, embolus or
hemorrhage. Thrombotic and embolic strokes are both classified as ischemic strokes
and account for 87% of all strokes. (4) Periods of ischemia quickly kill brain cells,
disrupting brain function and resulting in disability or death. Currently, there is only
one pharmacological treatment for stroke, tissue plasminogen activator (tPA), which
has a short therapeutic window and carries a significant risk of hemorrhage in the
periphery and in the brain. (5) Although acute mortality from stroke has declined due
to improvements in medical care, this has led to a growing number of stroke
survivors in our communities. Therefore, enhancing functional recovery and
preventing further disability in stroke patients is critical.
Advanced chronological age is the most important non-modifiable risk factor
for stroke. (6) Since >80% of strokes occur in individuals over the age of 65(2), the
aging population bears the major brunt of stroke related mortality and disability. Age
is an independent predictor of poor outcome after stroke, and older patients have
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both higher in-hospital mortality and poorer functional outcomes after an ischemic
event(2, 7), leading to high rates of nursing home placement, poor quality of life and
skyrocketing public health costs.(8)

1.2. Stroke and Respiratory Dysfunction
It is well documented that respiratory dysfunction, particularly during sleep, is
common following stroke and is associated with a worse prognosis. (9-13) More than
60% of individuals suffering a first stroke develop respiratory dysfunction
characterized by apneas and hypoventilation. (9) Over 80% of stroke survivors
initially diagnosed with stroke disordered breathing had continued deficits even three
years after their initial stroke. (14) Despite the high prevalence of stroke induced
respiratory dysfunction (SIRD), little is known about the mechanism by which stroke
affects breathing in part due to the lack of animal models of this disorder. Direct
lesions to brainstem respiratory centers can severely disrupt breathing. (15, 16)
However, patients with hemispheric strokes (the most common type of stroke) also
develop disordered breathing, and damage from these strokes do not directly affect
the brainstem. Additionally, there is a lack of correlation between respiratory
dysfunction and stroke location and/or severity.8 Disordered breathing that
accompanies stroke is associated with higher one-year mortality and worse
functional outcome at 3 months and 12 months following stroke. (17, 18) Importantly,
a decrease in cognitive performance was closely associated with the severity of
respiratory disturbance, and an increase in daytime sleepiness after stroke was a
strong predictor of cognitive decline.(19)
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A common type of stroke-induced periodic breathing is known as CheyneStokes respiration, which results from hyper-activation of the mechanism by which
the brain controls breathing in response to changes in tissue CO2/H+ (i.e., respiratory
chemoreceptors). Currently the only treatments available for stroke induced
respiratory disorders are physical interventions designed to maintain airway patency
i.e. continuous positive airway pressure (CPAP). Unfortunately, this type of
intervention is only marginally successful. Studies have shown that CPAP therapy
has proven beneficial in improving outcomes for stroke patients with obstructive
sleep apnea but not those with central sleep apnea. (20) Another study reported no
benefit from CPAP treatment during the sub-acute phase of stroke. (21) Further,
CPAP treatment is not well tolerated in recent stroke victims so patient adherence is
poor. (22) Therefore, an effective treatment of stroke-induced respiratory
dysfunction, particularly central apnea, is needed.

1.3. Respiratory dysfunction and cognitive decline
The majority of the evidence linking disordered breathing to cognitive decline
has come from studies of obstructive sleep apnea (OSA). OSA increases the risk of
cardiac and cerebrovascular events. It is has been shown that periods of intermittent
hypoxia can affect cerebral circulation and result in brain hypoperfusion(23, 24),
leading to decreased cerebral auto-regulation. (25, 26) In animal models of OSA,
cellular stress promotes white matter loss and axonal injury in brain regions such as
the hippocampus. (27, 28) Consistent with this finding, hypomyelination and
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impairments in long and short-term working memory have been seen in intermittent
hypoxia (IH) models such as sleep apnea(29).
Possibly due to this shared neuro-circuitry, sleep disturbances are common
among Alzheimer’s patients. Over 40% of patients with Alzheimer’s have evidence
of sleep-disordered breathing compared to only 5% of healthy controls. (30)
Evidence suggests that sleep disturbances can lead to a decline in cognitive function
and exacerbate memory impairment. Fragmented sleep and hypoxia induce a
neuroinflammaory state, disrupting neuronal plasticity and impairing hippocampal
dependent learning and memory. (31) Several studies have shown a link between
sleep apnea and executive function, working memory, episodic memory and
attention. (32, 33) In elderly women, those with sleep apnea are at a significantly
higher risk of developing cognitive impairment than controls. Females with sleep
apnea also exhibit increased white matter loss and changes in structural integrity in
several brain regions compared to age-matched males. (34) Although it did not
account for severity of sleep apnea and type or size of stroke, the REGARDS study
found a strong correlation between stroke and sleep apnea with poorer memory and
executive function compared to individuals with stroke or sleep apnea alone. Beyond
the cognitive damage that is sustained with the stroke itself, stroke patients have
accelerated cognitive decline in the years following the injury compared to controls,
which may be more pronounced in females. (35, 36) Poor cognitive function is a
strong predictor of nursing home placement and increases the length of
hospitalization. (37) The mechanism underlying “post-stroke cognitive decline” are

4

unknown. This thesis work specifically aims to answer the question: does disordered
breathing following stroke result in cognitive decline?

1.4. Respiratory physiology
Breathing is maintained by a negative feedback regulator designed to
maintain blood gas homeostasis (i.e., obtain O2 and eliminate CO2). Central and
peripheral chemoreceptors form the feedback portion of the control loop by adjusting
the rate and depth of breathing in response to changes in tissue CO2/H+ and O2.
The forward component of the respiratory control loop reflects effects of ventilation
on blood gases, and so determines the relationship between ventilation and arterial
CO2 (Fig.1.1). The stability of breathing depends on the sensitivity of the feedback
and forward components, which are referred to as controller (chemoreceptor) and
plant gain, respectively. Chemoreceptor gain is a linear relationship between
ventilation and arterial CO2, where the x-axis intercept represents the level of CO2
required to stimulate breathing (i.e., apneic threshold). Plant gain is reflected as an
isometabolic line, and where it intersects with chemoreceptor gain represents the
predicted equilibrium point (eupneic CO2). The difference between eupneic and
apneic CO2 (i.e., the CO2 reserve) is considered a key determinant of respiratory
stability; the larger the CO2 reserve the more breathing must increase to reduce
arterial CO2 to apneic threshold (Fig. 1.2). The CO2 reserve and consequently
respiratory stability varies inversely with both plant and chemoreceptor gain.
Therefore, an increase in either plant or chemoreceptor gain is predicted to
destabilize breathing. As long as the PaCO2 remains above apneic threshold there
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will be a constant stimulus to the respiratory network inducing rhythmic
breathing.(38, 39)
Respiration is mainly an autonomous activity determined by the metabolic
demands of the body. The pons and medulla have been identified as the anatomical
structures responsible for the autonomic control of respiration. (40) The medulla
contains a diverse set of respiratory neurons, divided into the ventral respiratory
group (VRG) and dorsal respiratory group (DRG), each with a distinct function
involved in respiratory control. This central site of respiratory activity is a point of
convergence of peripheral and central chemoreceptors, and is critical in maintaining
normal respiratory function. Central chemoreceptors communicate directly with the
central pattern generator (CPG), known as the Botzinger Complex. In coordination
with key respiratory neuronal populations such as the nucleus tract solitarius (NTS)
and the retrotrapezoid nucleus (RTN), the pacemaker and non-pacemaker cells of
the Botzinger complex controls rhythmic respiratory activity.
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Figure 1.1. Schematic of the feed back control of ventilation. Respiratory activity
is controlled by a combination of peripheral/central chemoreceptors and the central
pattern generator (CPG). Peripheral and central chemoreceptors receive stimulus
input in the form of PO2 and PCO2, respectively, communicating directly with the
central pattern generator. In response to changes in levels of PO2 and PCO2, the
CPG coordinates ventilation to maintain narrow parameters of ABGs. Stroke may
disrupt the breathing loop by altering the chemosensitivity of peripheral and central
receptors or by fluctuating the ventilatory response to levels of O2/CO2.
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Figure 1.2. Relationship between minute ventilation and arterial CO2. The linear
relationship between minute ventilation and arterial CO2 dictates that an increase in
minute ventilation produces a larger reduction in arterial CO2. Apneic threshold is a
measurable level of CO2 at which the drive to breath exists. Once the detectable
level of CO2 drops below threshold the drive to breath ceases. Increases in plant
gain (increase the effect of ventilation of ABGs) are predicated to destabilize
breathing by decreasing the CO2 reserve. Similarly, increases in chemoreceptor gain
(increase in ventilatory response to CO2) by eliciting a larger ventilatory response to
a misperception of ABGs are predicted to destabilize breathing.
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1.5. Central chemoreception
1.5.1. Retrotrapezoid Nucleus
Located in the rostroventrolateral medulla and part of the VRG, a population
of neurons referred to as the retrotrapezoid nucleus (RTN), functions as an
important site of central chemoreception. (41, 42) These neurons are intrinsically pH
sensitive, glutamatergic and project directly to the respiratory pattern generator.
Chemosensitive RTN neurons also express the transcription factor Phox2b, which is
considered a molecular signature of chemosensitive RTN neurons (Fig. 1.3). (43)
Mutations in this gene have been shown to cause severe respiratory deficits known
as congenital central hypoventilation syndrome (CCHS), also known as Ondine’s
Curse, the principal symptom of which is hypoventilation during sleep and reduced
or absent chemical drive to breath. Activation of RTN neurons expressing channel
rhodopsin increases both inspiratory and expiratory activity in conscious animals.
(44, 45) It has recently been shown that GPR4 channels in the RTN serve as the H+
sensing mechanism and disruption of these channels produces frequent apneas and
an altered CO2 evoked breathing response. (46) A common type of disordered
breathing, Cheyne-Stokes respiration, is thought to result from hyper-activation of
the chemo sensing mechanism by which the brain controls breathing in response to
changes in tissue CO2/H+, a form of breathing reproduced in our stroke model.
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Figure 1.3. Phox2b immunoreactivity of RTN neurons. 20x fluorescence image of
a 30-micron coronal brainstem slice. RTN neurons in the ventral medulla surface
characterized by transcription factor Phox2b immunoreactivity (yellow). Glial fibrillary
acidic protein GFAP (red), dapi (blue).
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1.5.1.1. KCNQ channels
The KCNQ family of K+ channels, namely KCNQ 2 and 3, found in the RTN,
are essential regulators of neuronal excitability and a K+ conductance known as Mcurrent. M-currents first activate at sub threshold potentials and increase outward K+
conductance as neurons approach action potential threshold. This outward K+ efflux
counteracts Na+ influx, preventing full action potential. (47, 48) These channels are
regulators of RTN excitability and can be pharmacologically manipulated to alter
responsiveness to carbon dioxide. Loss of function of either KCNQ channel 2 or 3
results in certain types of epilepsy and is proposed to contribute to apnea related
deaths in Sudden Unexplained Death in Epilepsy (SUDEP). (49-51) Specifically,
patients with KCNQ2 encephalopathy exhibit apnea with some reported cases of
SUDEP. (52) Furthermore, genetically engineered KCNQ2 knockout mice succumb
to respiratory failure within 24 hours of birth. (53) Pharmacological inhibition of RTN
KCNQ channels with XE991 increases both basal activity and responsiveness to
CO2 of RTN neurons both in vivo and in vitro. (54) In contrast, activation of KCNQ
channels with Retigabine decreases neuronal action potentials and silences RTN
activity. (54)

1.5.2. Nucleus Tract Solitarius
The Nucleus Tract Solitarius (NTS) is located in the dorsal medial aspect of
the medulla and is a point of central entry of cardiovascular and respiratory afferents
namely peripheral chemoreceptors, baroreceptors and pulmonary stretch receptors
relaying information on pH, O2, CO2 and blood pressure. (55, 56) Neurons of the
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NTS not only receive excitatory input from these afferent fibers in response to low
levels of PaO2, but are also capable of detecting changes in PaO2. (57) In response
to hypoxic conditions the NTS coordinates sympathetic and respiratory output to the
ventral lateral medulla and the CPG by increasing blood pressure and enhancing
ventilation. (58, 59) The NTS contains both glutamatergic and P2-purinergic
receptors, which influence the sympathetic response of the NTS. (60, 61) The NTS
projects axons to numerous areas including the ventral medullary surface,
respiratory pattern generator, as well as bulbospinal neurons that project to the
spinal cord to innervate respiratory associated muscles (Fig. 1.4).
In addition to contributing to the hypoxic ventilatory response, the neurons of
the NTS have been demonstrated to supplement the hypercapnic ventilatory
response (HCVR). Lesioning or pharmacological inhibition of these neurons
attenuates the HCVR. Many neurons of the NTS also express Phox2b, similar to
RTN neurons. The Phox2b transcription factor is required for normal development
and migration of reflex circuitry pathways of the autonomic system that persist
through adulthood. (62), Ablation of Phox2b NTS neurons with substance P-saporin
impairs HCVR but had no effect on basal activity under normocapnia(63) extending
the evidence that Phox2b expressing neurons are essential central chemoreceptors.
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Figure 1.4. Schematic of brainstem respiratory circuitry. NTS receives
peripheral input from the carotid bodies, aortic arch and baroreceptors detecting pH,
O2 and blood pressure, relaying information to the pre-Botzinger’s complex. RTN
central chemoreceptors monitor levels of CO2/H+ in the brain, also sending
projections to the pre-Botzinger’s complex.
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1.5.3. Astrocyte, purinergic signaling and central chemoreception
The traditional view of astrocytes is that they provide structural and metabolic
support to neurons, regulate blood flow and maintain blood brain barrier integrity.
(64) Under pathological conditions such as stroke, astrocytes become reactive,
markedly increasing the expression of glial fibrillary acidic protein (GFAP), the
hallmark signature of reactive gliosis, in response to intercellular signaling molecules
including but not limited to IL6, TNFα, TGFβ, INFγ and IL10 released from neurons,
microglia, monocytes and endothelial cells. (64) Reactive astrocytes have the
potential to alter their function and this can be both beneficial and detrimental to the
brain. (65) In response to cortical stroke, reactive astrocyte processes overlap
forming a persistent scar acting as a neuroprotective barrier to the ischemic site but
also increases infarct size while limiting neurological recovery. (66)
Research over the past decade has begun to elucidate additional dynamic
astrocytic functions. One is to modulate respiratory chemoreceptor activity in
response to hypercapnia through purinergic signaling, P2X and P2Y receptors. (67)
Injections of ATP in the region of the chemosensitive RTN increase respiratory
activity that can be reversed by application of the P2X antagonist, PPADS. (63, 67)
Ventral surface brainstem astrocytes sense extracellular pH changes and respond to
acidification through elevations of intracellular Ca2+ evoking ATP release, uniquely
different from cortical astrocytes. (68, 69)
This finding is not unique to RTN astrocytes, ATP injections into the region of
the NTS stimulate cardiorespiratory activity although P2 receptor blockade did not
alter the ventilator response to CO2/H+, suggesting an alternative mechanism by
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which astrocytes contribute to respiratory activity. It is proposed that astrocytes in
this region decrease glutamate uptake in response to acidification subsequently
increasing output of the NTS. (70) Besides the hypercapnic ventilatory response,
astrocytic purinergic signaling contributes to the hypoxic ventilatory response in the
pre-Botzinger complex, in which blockade of vesicular release of ATP reduces the
hypoxic ventilatory response. (71) Blockade of ATP release enhanced the secondary
response to hypoxia, respiratory depression, a product of normoxia combined with
hypocapnia. In response to hypoxia the respiratory system will increase minute
ventilation to improve oxygenation. In doing so levels of end tidal CO2 increase while
PaCO2 decreases. As PaO2 returns to normal, PaCO2 has plummeted below apneic
threshold producing a system with no chemical inputs resulting in apnea. By
controlling the ventilatory response to hypoxia, large fluctuations in arterial blood
gases can be avoided, stabilizing respiratory patterns, a major goal in treating the
clinical conditions of apnea and sleep disordered breathing.
Astrocytic end feet are closely associated with cerebrovasculature and
provide a vital role in regulating vascular tone in response to neuronal metabolic
demands(72) (Fig. 1.5). Recently, purinergic signaling has been shown to modulate
arterial tone in the region of the RTN. Disruption of this mechanism increases vessel
diameter and more importantly decreases the ventilatory response to CO2. (73)
Astrocytes play a seemingly vital role in contributing to respiratory chemoreception
while disrupting cellular functions alters the ventilator response to CO2. We
hypothesize that ischemic stroke induces brainstem reactive gliosis contributing to
respiratory dysfunction.
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Figure 1.5 Astrocyte end feet closely associate with vasculature. 40x confocal
image of GFAP staining of astrocytic (red) end feet “wrapping” around lectin stained
(green) cerebral brainstem vasculature. Dapi – blue.
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1.6. Disordered breathing
Sleep disordered breathing (SDB) refers to periods of reductions in breathing
amplitude or complete cessation of airflow which results in hypoxia, hypercapnia,
arousals and fragmented sleep. SDB is associated with increased morbidity and
mortality, and increases the risk of development of hypertension, stroke, cardiac
failure and diabetes. (74) Regardless of the subtype of disordered breathing,
patients suffer numerous episodes of hyponea or apnea per hour as defined by the
apnea-hyponea index. Five or more episodes an hour is classified as minor while 15
or more is severe. (75) During episodes of hypoventilation oxygen levels plummet
with concurrent increase in CO2 levels. Decreases in PaO2 levels stimulate the O2
sensing carotid body while rises in PaCO2 activate central chemoreceptors, resulting
in sympathetic excitation of brainstem neurons stimulating breathing, arousals and
producing fragmented and decreased quality of sleep.
Although Cheyne-Stokes respiration is proposed to be a result of alterations
in chemoreception, the underlying mechanism and circuitry remains to be
elucidated. There are many alterations that can produce disordered breathing
including chemosensitivity, plant gain or transport time delays of arterial blood flow
between the lungs and respiratory chemoreceptors. (76) All can result in periodic
breathing characterized by PaCO2 levels that drop below apneic threshold and
subsequently lead to apneas. (77) Following periods of apnea, PaCO2 levels rapidly
rise stimulating a large ventilatory overshoot, which lowers PaCO2 levels below
apneic threshold. Concurrently, during periods of apnea PaO2 levels plummet
resulting in hypoxia.
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Disordered breathing with recurrent apneas is associated with intermittent
hypoxia, defined as an apneic period of sufficient duration to cause a >3% drop in
oxygen

saturation

of

hemoglobin.

(78)

Hypoxemia

activates

peripheral

chemoreceptors in the aortic arch and carotid bodies potentiated by catecholamines.
Peripheral afferent fibers integrate with the brainstem respiratory network innervating
the respiratory pattern generator. In response to hypoxia alone, respiratory
frequency and tidal volume increase, raising levels of PaO2 while decreasing levels
of PaCO2. An unfortunate byproduct of this response is O2 levels above threshold
and CO2 levels below apneic threshold resulting in apnea. Hypercapnia and hypoxia
following apnea can synergistically stimulate the sympathetic response further
complicating this matter.

1.7. TGFβ increases in the ipsilateral hemisphere following stroke
Transforming Growth Factor Beta (TGFβ) is a multifunctional cytokine
belonging to the large transforming growth factor family.

It has many cellular

functions in both development/embryogenesis and adulthood, including cell growth,
differentiation,

apoptosis

and

a

context

dependent

activation/inhibition

of

inflammation. (79) TGFβ can be secreted as four different latent isoforms, named
TGFβ1-4, that become active following proteolytic cleavage and binding to the type II
TFGβ receptor. (80) Binding with the TGFβ receptor initiates the SMAD signaling
pathway, resulting in phosphorylation of SMAD proteins, with the RSMAD/coSmad
complex translocating to the nucleus, binding various transcriptional promoter sites,
and altering expression of a variety of genes. TGFβ activity can be evaluated by
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measuring the downstream effects on the SMAD signaling pathway, specifically
phosphorylated SMAD2 (Fig. 1.6).(81)
The TFGβ receptor is expressed on all major cell types of the brain, including
neurons, microglia and astrocytes. (82) After brain injury TGFβ has powerful effects
on the immune system, being both pro and anti-inflammatory depending on the cell
type and context. In the setting of experimental stroke TFGβ expression remains
elevated for a week and is thought to be neuroprotective, as blocking TGFβ1
signaling exacerbates injury. (83, 84) Activated microglia and macrophages appear
to be the source of TGFβ following ischemic stroke and signal in an autocrine
manner promoting an anti-inflammatory phenotype resulting in a wound healing
response. Activated astrocytes also upregulate TGFβ signaling during ischemic
stroke as evidenced by increased pSmad2 promoting reactive gliosis and scar
formation (Fig. 1.6).(85)Inhibition of TGFβ signaling via the Smad3 pathway
improves wound healing and decreases scar formation, as evidenced by decreased
GFAP immunoreactivity and fibronectin expression in a brain stab wound model.
(86) Glial scar formation is proposed to be detrimental to post stroke recovery
preventing neurogenesis and angiogenesis in the infarct region. (87) The effect of
TGFβ on astrocytes outside the infarct region remains to be elucidated. The varying
roles of the different TGFβ isoforms further complicate this matter.
The amount of TGF-β in the aged 18-month-old murine brain was elevated
compared to that of a 5-month-old brain while following a similar time course of
expression; these levels further increase following ischemic stroke. Interestingly,
baseline levels of TGF-B do not fluctuate with sex though sex based changes in the
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aged brain in response to stroke are still unknown. (85) Corresponding with findings
of increased TGFβ expression is evidence of an accelerated glial reactivity in aged
brain following cerebral ischemia, resulting in premature scar formation hindering
post stroke recovery. (88) Early scar formation is also associated with an untimely
accumulation of BRD-U positive astrocytes further indicative of proliferation and
reactive gliosis. (89)
In the aged brain activated microglia produce an exaggerated level of
cytokines contributing to a prolonged neuroinflammatory condition. Following
immune challenge, astrocytes will respond to IL-10 in turn attenuating microglia
activation in a TGF-β1/Smad3 dependent manner. (90) Inhibition of this signaling in
young mice prolonged sickness behavior while amplifying the pro inflammatory
cytokine profile in LPS challenged mice. (91) Following immune challenge,
astrocytes from the aged brain show a 3 fold increase in GFAP expression
compared to young counterparts as well as decreased expression of IL-10
receptor,(92)suggesting a dysfunctional reactive astrocyte profile contributing to an
increase in neuroinflammation. Interestingly, the TGF-B1/Smad3 signaling pathway
is also impaired in aged mice promoting further neuronal dysfunction and
neurodegenerative disease. Differential astrocyte reactivity in the aged brain could
explain, at least partially, why aged animals display worse functional outcomes and
may contribute to the development of disordered breathing and further cognitive
impairment.
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Figure 1.6. TGF-β signaling and MCAO induced astrogliosis. (A) Schematic of
TGF-β signaling pathway via phosphorylation of SMAD2/3 complex leading to
increased GFAP expression and fibrosis. (B) Fluorescence image of a day 3 post
stroke 10x mosaic coronal slice depicting increased astrocyte expression of GFAP
on ipsilateral side. 20x image of yellow reference frame shown. (C) Day 42-post
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stroke coronal slice of GFAP staining depicting glial scar formation surrounding
injury. 20x image of yellow reference frame shown. GFAP-red, dapi – blue.
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1.8. Acetazolamide and cerebral blood flow
Carbonic anhydrase is an enzyme that catalyzes the removal of a water
molecule from carbonic acid predominantly expressed in blood cells and exerting its
effects on the kidney allowing for the reabsorption of bicarbonate and other
electrolytes. (93) Acetazolamide, also known as Diamox, is a carbonic anhydrous
inhibitor that prevents the reabsorption of bicarbonate in the kidneys and increases
its excretion. According to Le Chatelier’s principle the carbonic acid equation shifts
towards an increase in bicarbonate and hydrogen ions, lowering blood pH, which
can modulate respiratory neuronal excitability. Acetazolamide has shown promise in
the treatment of intracranial hypertension, altitude sickness and obstructive sleep
apnea. (94-96) In the treatment of obstructive sleep apnea, Acetazolamide is
proposed to improve breathing by either decreasing the efficacy of CO2 removal, i.e.
decreasing plant gain, or by increasing neuronal excitability by increasing H+
concentration.
It has been well established that acetazolamide’s increases cerebral blood
flow. A balance between intraluminal pressure and interstitial pressure regulates
regional blood flow. The water-shed channel, aquaporin 4 (AQP4), has been shown
to regulate this balance. As interstitial water flow increases vascular diameter
decreases and subsequent blood flow decreases. (97, 98) AQP4 channels are
inhibited by H+ under physiological conditions, decreasing interstitial flow while
increasing regional blood flow. Recently, MRI has demonstrated that regional neural
activity increase H+ concentration while increasing blood flow. (99) Furthermore,
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acetazolamide administration results in accumulation of extracellular H+, increased
capillary dilation and cerebral blood flow (Fig. 1.7).(100)
Cerebral autoregulation maintains constant blood flow irrespective of
pressure changes to meet regional metabolic demands. (101) Increase in
concentrations of metabolites such as CO2 and H+ induce vascular changes that
lead to an increase blood flow. (102, 103) This in turn facilitates removal of excess
metabolites, matching blood flow to metabolic need. (104) Respiration is one method
in which the body regulates the removal of CO2/H+, which is initiated by respiratory
centers and leads to an increase in minute ventilation. If the vasculature surrounding
key respiratory neuronal populations responded to CO2/H+ in a similar manner as
other vessels in the cerebral vascular bed, this would facilitate the removal of
CO2/H+ limiting the ability of respiratory chemoreceptor to detect these metabolites.
(105) Recently this concept of reversed vascular reactivity has been demonstrated in
the arterioles in the RTN. Arterioles in this region and the cortex are differentially
regulated during exposure to CO2/H+ via purinergic signaling. (73) Whereas the
vasculature in the cortex dilates in the presence of CO2/H+, RTN arterioles constrict
following identical stimuli.
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Figure 1.7. Astrocyte aquaporin 4 mediated control of regional cerebral blood
flow. Regional cerebral blood flow is regulated by an equilibrium between
intraluminal and interstitial pressure. Intraluminal pressure is maintained by cerebral
autoregulation, while interstitial pressure is predominantly sustained by bulk water
flow through astrocytic aquaporin 4 channels (Aqp4). Aqp4 channels are inhibited by
excess H+, decreasing interstitial pressure, subsequently leading to vasodilation and
increase regional blood flow.
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1.9. Objectives
The objective of this thesis is to determine if a mouse model of ischemic
stroke produces disordered breathing recapitulating the phenotype seen in clinical
populations. Numerous studies have reported stroke patients with disordered
breathing have worse functional and cognitive outcomes than those with stroke
alone. (17-19) The first step towards treatment of the negative consequences of
SIRD is the development of appropriate animal models to study the pathophysiology
of SIRD and to test potential pharmacological agents. My central hypothesis is that
stroke will induce chronic respiratory instability and apnea in mice, and that this is
linked to higher mortality and greater post-stroke cognitive deficits. As the aging
population suffers the brunt of stroke related morbidity and mortality it is critical to
investigate the mechanisms contributing to these factors. Previously, we have found
that although aged male mice have similar size infarcts as females they suffer higher
mortality and functional deficits compared to aged females. This poor recovery
witnessed in aged males may be linked to respiratory dysfunction. I expect aged
male animals will have a slower recovery following MCAO compared to young
animals and that the severity of disordered breathing will correlate with poorer
cognitive outcomes.
The mechanisms that lead to post-stroke respiratory dysfunction are
unknown. The contribution of central apnea to progressive cognitive decline that is
seen after stroke is also unclear. This work specifically aims to answer the
questions: does disordered breathing occur after stroke in animal models? Is this
worse in aged animals? Does the severity of post stroke respiratory dysfunction
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correlate with post-stroke cognitive decline? We performed longitudinal studies in
young and aged mice to evaluate the prevalence and evolution of post-stroke
disordered breathing. We then examined how post-stroke respiratory dysfunction
contributed to progressive cognitive decline. Next we assessed the role of TGF-β
induced astrogliosis and subsequent respiratory dysfunction.
Lastly we determined if targeting specific aspects of respiratory control could
improve the breathing phenotype leading to an enhancement in long-term recovery
after stroke. We employed various pharmacological techniques to manipulate plant
gain in order to suppress hypoxic apneic events. We proposed the following three
aims to answer these questions (Fig. 1.8).

Aim 1: Determine the phenotype of stroke disordered breathing across age
and sex. The MCAO model of ischemic stroke produces a disordered breathing
phenotype characterized by a decrease in respiratory frequency as well as an
increase in incidence of spontaneous apneas. Prior work has shown that the
response to stroke differs dramatically based on both the age and sex of the animal
examined. We have examined young (2-3 month) and aged (18-20 month) male and
female mice and discovered that aged males present with a severe form of
disordered breathing while aged females display a very mild phenotype.

Aim 2: Assess the severity of stroke induced respiratory dysfunction and its
relationship with post-stroke progressive cognitive decline. We will employ the
MCAO model of ischemic stroke to replicate the disordered breathing phenotype
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seen in the clinical stroke population. Utilizing this pattern of respiratory instability we
will explore the severity of disordered breathing, progression of cognitive decline and
overall outcomes across both age and sex over a six-week period. Lastly, we will
explore if increased TFG-β expression following ischemic stroke contributes to brain
stem glial cell reactivity and respiratory dysfunction.

Aim 3: Targeting stroke induced respiratory dysfunction to improve
neurological recovery. Apneas are a central trait of disordered breathing and
produce numerous physiological changes. Manipulating individual components of
the respiratory control system may stabilize respiratory activity, eliminate hypoxic
events and promote the maintenance of normal blood levels of O2 and CO2. This will
reduce progressive insults to neuronal tissue and improve cognitive outcomes after
stroke. Preliminary evidence shows that administration of Acetazolamide stabilizes
respiratory activity by eliminating apneas. We propose continuous treatment with
Acetazolamide will not only stabilize respiratory instability but will also reduce poststroke cognitive deficits.

This work will not only develop a model of stroke induced respiratory
dysfunction that recapitulates the respiratory phenotype seen in the clinical
population, but will also provide significant translational relevance to the field of
stroke, aging, and cognitive decline. We have integrated studies to examine SIRD in
both males and females, as our preliminary studies have shown significant
differences in respiratory function after stroke based on the sex of the animal
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examined, recapitulating clinical data. Successful treatment of SIRD may lead to
significant improvements in post-stroke recovery and cognition, resulting in improved
outcomes and prevention of further disability.
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Figure 1.8. Schematic overview of experimental aims.
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Chapter 2. Materials and Methods.
2.1. Animals
Young (8-12 weeks, 21-27g) C57/B6 male and female mice were purchased
from Jackson Laboratories. Aged C57/B6 mice (18-21 months) of both sexes were
obtained from the National Institute on Aging. All mice were housed in a
temperature- and humidity-controlled vivarium, 5 per cage (11”L, 6”W, 6”H) with a
12-hour light/dark schedule with ad libitum access to food and water for 4 weeks
after arrival. All experiments were performed according to NIH guidelines for the
care and use of animals in research and under protocols approved by the University
of Texas Health Science Center Houston Institutional Animal Care and Use
Committee.
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Cohort

Sacrifice

Plethysmography

Day 7

Brainstem Histology

Day 3

Arterial Blood Gases

Day 3

Pulse Oximetry

Day 3

Perfused

42 day studies of cognitive outcomes

Day 42

IHC/CV/Western

Distal MCAO

Day 42

IHC/CV

Cohorts for each: Acute Retigabine/XE991/

Day 7

Perfused

Chronic Acetazolamide

Day 42

IHC/CV/Western

TGF- β

Day 7

IHC

TTC & Fluorojade

Actazolamide Assessment

Table 1. Cohort Table.
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2.2. Middle cerebral artery occlusion
Focal transient ischemia was induced by middle cerebral artery occlusion for
60 minutes under Isoflurane anesthesia followed by reperfusion as described
previously. (106, 107) Briefly, mice were placed prone onto a heating pad and a
midline incision was made into the skin. The carotid artery was ligated to allow for
placement of a silicon filament through the external carotid into the internal carotid,
which allowed access to the middle cerebral artery (MCA). An 80% drop in cerebral
blood flow confirmed occlusion of the MCA by Laser Doppler (Moore Instruments).
After 60 minutes of occlusion the silicone filament was withdrawn, the surgical site
was sutured and the animals were returned to home cages and monitored. The
same procedure was conducted in sham animals except the silicone filament was
not introduced past the internal carotid. Body temperatures were monitored rectally
and maintained at approximately 37 °C.

2.3. Neurological-Deficit Score (NDS)
Mice were given a neurological-deficit score as previously described. (108)
Neurological deficits were scored using the following rubric on a scale from 0-5: 0 =
no deficit, 1 = forelimb weakness and torso turning to ipsilateral side when held by
the tail, 2 = circling to affected side; 3 = unable to bear weight on affected side and
circling immediately when placed on a bench, 4 = no spontaneous locomotor activity
or barrel rolling, and 5 = dead.
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2.4. Distal middle cerebral artery occlusion
Mice were subjected to permanent distal middle cerebral artery occlusion
(pDMCAO) as previously described. (109) Following this, the right dorsolateral
cranium was shaved and a 1cm2 skin flap was cut over the temporalis muscle, which
was then incised with Vannas scissors to expose the temporal bone. The skull was
scrubbed with sterile saline and a 2 mm burr hole was drilled over the middle
cerebral artery, immediately dorsal to the zygomatic arch. The dura were reflected
with sharp forceps and the middle cerebral artery washed with sterile saline. Stroke
was then induced by 1-2 seconds of low temperature cauterization of the exposed
middle cerebral artery, and ischemia confirmed by laser doppler as a greater than
90% drop in blood flow to the cortex distal to the occlusion. Following successful
induction of ischemia, the burr hole was closed with dental cement, the temporalis
muscle incision repaired with Vetbond and the skin incision closed with Vicryl 5-0
nylon sutures. Sham surgeries were performed following an identical procedure,
except that no cauterization was performed.

2.5. Whole body plethysmography
Respiratory parameters (frequency, tidal volume, minute ventilation, # of
apneas) were measured using whole body plethysmography, a well-established
technique for respiratory activity. (110, 111) Mice were placed individually into a
ventilated (1L/min) plexiglass chamber and allowed 1 hour to acclimate. Inspiration
and expiration result in decreases or increases in chamber pressure relative to a
reference chamber that are detected using a pressure transducer, which is
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calibrated prior to every experiment. Tidal volume (ml, normalized to body weight
and corrected for chamber temperature, pressure and humidity) and respiratory
frequency (breaths/min) will be recorded on a breath-to-breath basis and analyzed
from periods of relative quiescence during the last 2 minutes of each experimental
condition; the product of tidal volume and frequency is minute ventilation (ml/min/g).
The frequency of apneas (defined as ≥3 or more missed breaths) will be determined
for the duration of the recording. We confirmed that the section of data selected for
analysis is devoid of behavior artifacts and is most representative of each animal’s
breathing pattern. All animals received baseline assessment of respiratory activity
prior to undergoing surgery. Central chemosensitivity was assessed starting 3 days
after surgery by exposing animals to graded hypercapnia (3, 5 and 7% CO2
balanced O2; 5 minutes per condition). During a separate period of testing peripheral
chemoreflexes were assessed by exposing animals to 5 minutes of hypoxia (10% O2
balanced N2) to stimulate carotid chemoreceptors. Control of gases and calculation
of respiratory parameters was controlled by Buxico Finepoint software (DSI).

2.6. Arterial blood gas analysis
A small volume of blood (100ul) was collected via a cannula surgically
implanted into the carotid artery on day 3-post surgery to measure arterial blood
gases (ABG) and analyzed using CG8+ iStat cartridges (Abbott).
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2.7. O2 consumption
To assess differences in metabolic activity animals were placed in individual
chambers where they were allowed to move freely and have access to food and
water. Under room air conditions O2 consumption was measured using Oxymax
(CLAMS) open flow system as described. (112) Levels of O2 and CO2 were
measured for 24 hours to capture both wake and rest periods.

2.8. Pulse oximetry
On day 3-post surgery pulse oximetry measurements (SpO2) were recording
using MouseOx neck collar (Starr Life Sciences Corp.). Collars were place around
shaved neck of both stroke and sham mice. Mice were returned to their home cages
and allowed to acclimate to the collars. Recordings were taken during periods of
time when the animals were at rest (calmly sitting in cage without any signs of
distress or motor activity).

2.9. Histological assessment
Mice were anesthetized with a 0.1mL/10g body weight dose of Avertin
(T48402, Sigma-Aldrich) dissolved in 2-Methyl-2-Butanol. Animals were perfused
transcardially with phosphate-buffered saline followed by 4% paraformaldehyde.
The brain was removed from the skull, post-fixed for 24 h, and subsequently placed
in cyroprotectant (30% sucrose). The brain tissue was cut into 30-µm free-floating
coronal sections and was stained using cresyl violet (CV, C5042, Sigma-Aldrich) for
evaluation of ischemic cell damage. Images were acquired by a charge-coupled
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device camera (Micropublisher 5.0 RTV, QImaging) and analyzed using Sigmascan
Pro5 (Systat Software Inc.) as described. (113) Atrophy volumes were expressed as
a percentage of the ipsilateral hemisphere. Animals were excluded if they had a
posterior cerebral artery occlusion or no intra-ischemic deficits.

2.10. 2,3,5-triphenyltetrazolium chloride (TTC) staining
Brains were extracted after euthanasia and cut into five 2-mm coronal
sections, and stained with 1.5% 2,3,5 triphenyltetrazolium chloride (TTC) as
performed. (114) This stain is used to distinguish between metabolically active
versus inactive tissue, here it is used as a measurement of infarct size.

2.11. Fluorojade staining
Thirty micron sections were slide mounted and stained for degenerating
neurons(115)

using

Fluorojade

(EMD

Millipore)

following

manufacturer’s

recommendations.

2.12. Immunohistochemistry
Thirty micron sections were slide mounted and heat induced antigen retrieval
was performed using citrate acid pH 6. Permeabilized in 0.15% TritonX in PBS and
blocked in 10% Normal Donkey Serum / 1% Bovine Serum Albumin (Sigma).
Sections were incubated overnight with rabbit anti-pSmad2 (1:200, Abcam), CY3
conjugated GFAP (EMD Millipore) and then incubated for 60 min with anti-host
antibody conjugated with a fluorophore (1:1000), DAPI nuclear stain solution
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(1:1000; Invitrogen), and images were then taken using an inverted light Leica
fluorescence microscope. Quantifications performed with Leica LAS X software
platform.

2.13. Acetazolamide administration
For acute studies mice received a 40mg/kg subcutaneous (SQ) or vehicle
injection day 3 post surgery. For long term studies osmotically driven alzet pumps
(Alzet) filled with acetazolamide or saline were surgically placed SQ on day 14
following surgery. Following manufacturer’s instructions for pump priming, animals
were placed prone under Isoflurane anesthesia and a small SQ incision was made
between the shoulder blades. A pair of blunt sterile scissors was introduced into the
incision and slowly advanced to create a pocket for pump placement. Following
pump placement the wound was sutured closed and a local anesthetic was
administered. Animals were monitored daily for wound healing and to make sure the
pump stayed in place.

2.14. Retigabine and XE991 administration
As discussed earlier, subthreshold K+ conductance is produced by KCNQ
channels which regulate basal activity of chemo sensitive RTN neurons. (54) We
employ Retigabine a KCNQ channel agonist and XE991, a KCNQ channel
antagonist, to decrease and increase respiratory instability respectively. Retigabine
(10mg/kg) or DMSO vehicle was administered SQ day 3 post surgery. XE991
(2mg/kg) or DMSO vehicle was administered SQ on day 3 post surgery.
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2.15. Transforming Growth Factor-Beta (TFG- B) administration
TGF-B

or

vehicle

(5

uL

sterile

saline)

was

administered

by

intracerebroventricular (ICV) injection into naïve mice under Isoflurane anesthesia
under stereotaxic guidance. (116) A burr hole was made with the tip of a 30 gauge
needle in the right skull at the coordinates -0.9mm lateral and -0.1mm posterior from
Bregma, followed by needle insertion of a 10 uL, 33 gauge syringe (Model 701 SN,
Hamilton Company) to a depth of -3.1mm. 5 ul of TFG-B or vehicle was injected over
2 minutes. The needle was left in place for 5 minutes to prevent efflux of solution.

2.16. Behavioral tests
2.16.1. Novel Object Recognition Test (NORT)
This test was conducted in a quiet temperature controlled room. Mice are
individually place into separate plexiglass rectangular boxes with 2 identical objects,
termed familiar objects, equally placed on each side. Mice are allowed to freely
explore the chamber and objects for 10 minutes. At the end of the training period
mice are returned to their home cage for 5 minutes. During this time the chambers
are cleaned and one of the objects in each arena is replaced with a novel object of
different shape, size and color. At the conclusion of the 5-minute rest period mice
were placed into the same chamber as the training probe and again allowed to freely
explore for 10 minutes. Following this test trial mice were returned to their home
cage and the test was concluded. Both the training and test trials were recorded
using a video tracking system (Noldus EthioVision XT) via an overhead mounted
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camera. Familiar and Novel objects were identical for all mice. New novel objects
were used during subsequent testing periods.
2.16.2. Barnes Maze
Barnes maze was conducted on an elevated circular platform (92cm
diameter) with 20 evenly spaced holes (5cm diameter). (117) A randomly chosen
hole was designated as the escape hole, which allowed the animal to escape the
platform into a dark rectangular box below. During training trials, mice learn the
location of the escape hole by spatial clues positioned around the platform. All
training trials and the test trial were performed in a dark room with the platform lit by
bright white light. Animals received 3 training trials followed by a test trial 4 hours
later on day 21 or 42-post surgery. During the first training trial, the mouse was
placed into the center of the arena and then guided to the escape hole by a clear
cylindrical chamber, which it was allowed to explore for 1 minute. During the second
and third trials the animal was again placed into the center of the platform and
allowed to freely explore the arena for 5 minutes. At the end of each trial if the
animal did not find the escape hole it was guided to it using the same clear chamber.
The arena was cleaned between trials. The testing period consisted of one 3-minute
trial. The trial was terminated when the animal entered the escape hole or at the end
of the 3 minute period. Any animal that did not find the escape hole once during any
training trial was excluded. A camera was mounted above the maze to monitor
performance through a video tracking system (Noldus EthoVision XT).
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2.16.3. Contextual fear conditioning
Animals were allowed to acclimate to a square plexiglass container with metal
grid floor (Harvard Apparatus) for 2 minutes on day 42 post surgery. Two opposing
walls of the chamber displayed different patterns, the back wall was white and the
front wall was clear. Contextual chambers were inside a larger soundproof box lite
by white light and closed during acclimation, training and testing trials. Chambers
were cleaned prior to use and between animals with scented wipes. White noise was
played inside the box. Following all acclimation trials animals were placed back into
the plexiglass container for 2 minutes then received a 0.7mA shock through the
metal grid floor lasting 2 seconds. Animals were then returned to their home cage.
24 hours later animals were again placed in the contextual fear chambers and the
session was recorded for 3 minutes. (Noluds EthioVision XT) The amount percent of
time the animal spent freezing was calculated. (118)

2.16.4. Corner test
This test detects integrated sensory-motor function as it involves stimulation
of vibrissae sensory) and rearing (motor). This test was carried out as described.
(119) Briefly, a mouse is encouraged to enter a 30-degree corner created by two
cardboard pieces. Once in the corner, the boards stimulate both sides of the
vibrissae, the mouse then rears forward and up, turning to face the open end.
Twenty trials are performed and the percentage of right turns is calculated.
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2.17. Statistical analysis
Statistics are presented as means ± SEM for all experiments. Statistics were
performed using GraphPad Prism 7.

Interval power analysis was performed to

determine group size. A student’s t-test was used when comparing 2 groups and a
2-way ANOVA was performed when comparing multiple groups. If an interaction was
statistically significant, then Sidak’s post-hoc analysis was used to assess where the
interaction occurred. If there was no significant interaction, main effects were
reported when significance. Linear regression analysis was used to assess changes
in chemosensitivity. A probability value of p<0.05 was considered statistically
significant. All investigators were blinded to surgical condition when analyzing data.
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Chapter 3. Stroke Induces Respiratory Dysfunction
Characterized By Apneas and Hypoxia.
Rationale: Stroke induced respiratory dysfunction is highly prevalent amongst
individuals suffering a first time stroke. Patients suffering respiratory dysfunction,
characterized by apneas and periods of hypoxia, have worse functional outcomes
and demonstrate progressive cognitive decline following ischemic stroke. CPAP, the
only approved therapy for respiratory dysfunction, is poorly tolerated by stroke
patients and has proven futile in improving respiratory activity. This first step towards
treatment of the negative consequences of SIRD is the development of appropriate
animal models that will allow us to explore the pathophysiology of SIRD and provide
us with the opportunity to test potential pharmacological agents.

3.1. Middle cerebral artery occlusion produces disordered breathing characterized
by hypoventilation and increased apneas.
To determine if MCAO produces disordered breathing 6-8 week old male
mice were subject to 60 minutes of MCAO or sham surgery. To establish baseline
respiratory activity mice underwent plethysmography testing as described in 2.4 1day prior to surgery. On day 3-post surgery mice underwent plethysmography to
identify the phenotype of stroke induced respiratory dysfunction. Respiratory
frequency, measured as breaths per minute, decreased compared to sham,
(164.4±5.09 stroke vs. 286.7±13.97 sham) respectively, p<0.0001 (Fig. 3.1a). Stroke
mice displayed an increase in tidal volume (ml/min), although not significant,
(0.0079±0.0003 stroke vs. 0.006±0.0004 sham), p=0.06, Fig. 3.1b). Under room air
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conditions minute ventilation (ml/min/kg) was decreased compared to sham,
(1.244±0.24 stroke vs. 2.037±0.24 sham, p<0.01, Fig. 3.1c). Strikingly, stroke mice
(6.8±1.7) display an increase incidence of apneas of compared to baseline (1.2±0.4)
or sham (0.8±0.8), p<0.01 (Fig. 3.1d). Representative waveforms of respiratory
activity shown of baseline sham, and stroke respectively. (Fig. 3.1e) n=12.
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Figure 3.1. Phenotype of stroke induced respiratory dysfunction. Whole body
plethysmography was performed on stroke and sham mice day 3 post surgery.
Under room air conditions respiratory frequency, measured in breaths per minute,
decreased, 164.4±5.09 and 286.7±13.97, p<0.0001 (A) while tidal volume (ml/g)
increased although not significantly, 0.006±0.0004 vs. 0.0079±0.0003, p=0.06 (B).
The product of frequency and tidal volume, minute ventilation (ml/min/g), decreased
(C) following MCAO, suggestion hypoventilation, 1.244±0.24 vs. 2.037±0.24, p<0.01.
The number of apneas per minute markedly increased following stroke,
6.8±1.7±0.8±0.8, p<0.01 (D). Representative respiratory waveform tracings of mice
at baseline, sham and stroke are shown (E). n=14
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3.2. Respiratory dysfunction results in hypoxia & hemoglobin desaturation.
To determine if changes in respiratory parameters following MCAO had
physiological consequences both stroke and sham mice underwent arterial blood
gas analysis and pulse oximetry monitoring on day 3 following surgery. Arterial blood
gas analysis found that stroke mice had a decreased level of PaO2 (104±4.7 vs.
79.3±0.57, p<0.05), and an increased PaCO2 level (33.9±5.1 vs. 48.1±0.8, p=0.5)
while pH remained unchanged (7.35±0.02 vs. 7.37±0.01, n=3). (Table 2.)
Stroke mice undergoing pulse oximetry monitoring displayed oscillations in
their hemoglobin saturation levels (SpO2). Baseline SpO2 levels fluctuated between
94-96% and would periodically drop between 80-90% based on the duration of the
apnea. Sham mice consistently maintained a SpO2 level between 97-100%.
Representative tracings shown (Fig3.2).
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Table 2. Arterial blood gases. Obtained day 3 following surgery from stroke and
sham mice. Stroke mice have an increase in PaCO2, 33.9±5.1 vs. 48.1±0.8, p=0.5,
and a decrease in PaO2, 104±4.7 vs. 79.3±0.57, p<0.05, suggesting a state of
hypercapnia and hypoxia. pH remained unchanged 7.35±0.02 vs. 7.37±0.01, n=3.
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Figure 3.2. Pulse oximetry tracings day 3 post surgery. Oxygen hemoglobin
saturation is maintained between 97-100% in sham mice. SpO2 levels drop in stroke
mice representing intermittent hypoxia. A 3-4% drop in SpO2 is considered an
indicator of a hypoxic event, p<0.05 n=3
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3.3. Ischemic stroke does not alter chemoreceptor gain as measured by whole body
plethysmography.
As part of whole body plethysmography testing mice were exposed to 100%
O2 and a graded CO2 response to assess changes in the central chemoreflex. Under
conditions of increased atmospheric O2 peripheral chemoreceptor input is silent
allowing for the assessment of CO2/H+ driven central chemoreceptors. (120) Both
respiratory frequency and minute ventilation were blunted across all air conditions
compared to sham. (Fig. 3.3a) No difference was observed between stroke and
sham in the slope of the ventilatory response to CO2 across the four gas conditions
as a measure of chemosensitivity, sham=0.38, stroke=0.34, p=0.77. (Fig. 3.3b)

51

Figure 3.3. MCAO does not alter CO2/H+ sensitivity. Minute ventilatory response
to CO2 is slightly blunted, evident by the right shift in minute ventilatory response to
CO2, following 60 minute MCAO in young male mice (A). The slope of the minute
ventilatory response to CO2 is unchanged following MCAO (B), slope sham=0.38,
stroke=0.34, p=0.77. n=14
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3.4. Peripheral chemoreflex.
To understand if MCAO disrupts the hypoxic ventilatory response, mice
underwent plethysmography recordings with exposure to 21% O2 (room air) followed
by 10% O2. Day 3 post surgery the minute ventilatory response to hypoxia of stroke
mice was blunted (2.02±0.15 vs. 1.51±0.28, p<0.05), yet the chemosensitivity to
hypoxia remained unchanged. Slope of the chemosensitivity to hypoxia in
sham=0.03, stroke=0.04, difference between the slopes was not significant, p=0.73.
(Fig. 3.4) n=14
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Figure 3.4. Hypoxic ventilatory response. Ventilation and the ventilatory response
to hypoxia are blunted following MCAO. Yet, the chemosensitivity to hypoxia
remains unaltered. Slope sham=0.03, stroke=0.04, difference between the slopes
was not significant, p=0.73.

54

3.5. MCAO does not result in brainstem cell death.
To rule out brainstem neuronal cell death as a causative factor of disordered
breathing, tissue was assessed for histological damage at day 3-post surgery. No
cell death or neuronal degeneration was observed in the brainstem as evidenced by
either TTC staining or Fluorojade staining. (Fig. 3.5) TTC staining is used as a
marker metabolically active tissue and is used to distinguish healthy neuronal tissue
from infarcted. It is enzymatically reduced to a red color in living tissue and will
remain white in infarcted regions. Fluorojade staining is used as a marker of
degenerating neurons.
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Figure 3.5. MCAO does not result in direct brainstem cell death. Brainstem cell
death was assessed by both TTC (A) and fluorojade staining (B) on day 3 following
MCAO. MCAO produces a large wedge shaped infarct in the hemisphere indicated
by lack of “red” staining by TTC. The brainstem was unaffected (A). Fluorojade, a
marker for degenerating neurons, was positive in the striatum of the right
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hemisphere in mice that underwent MCAO. The brainstem was negative for any
fluorojade positive cells, n=3. Fluorojade green, dapi blue.

3.6. Ischemic stroke does not alter basal metabolic activity.
To determine if factors other than deficits in central respiratory circuitry
contribute to stroke disordered breathing, mice underwent metabolic activity
assessments. Stroke has the potential to alter other parameters such as body
temperature, food intake and overall energy expenditure. Systemic energy
metabolism can be evaluated by monitoring the volume of oxygen consumption in
individual animals. (121) If stroke were to decrease energy expenditure in mice,
metabolic activity would therefore decrease (observed by decrease in O2
consumption). A decrease in O2 consumption would present as a decrease in minute
ventilation on whole body plethysmography, similar to our observed outcomes.
Stroke had a negligible effect on O2 consumption compared to sham on day 7, 21 or
42-post surgery. Day 7 data shown (Fig. 3.7) (sham 56.75±4.37 vs. 65.35±4.5,
p=0.24). This further supports the conclusion that disordered breathing is a
consequence of stroke, not a compensatory response to a decrease in activity or
alterations in metabolic activity.
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Figure 3.6. Oxygen consumption as a measurement of metabolic activity.
Metabolic activity was assessed on day 3-post surgery. The volume of oxygen
consumed was recorded every 10 minutes and averaged per mouse over a 4-hour
period during resting hours. MCAO did not alter basal metabolic activity, minimizing
the possibility that alterations in metabolic activity contributions to SIRD. Sham
56.75±4.37 vs. 65.35±4.5, p=0.24, n=5.
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3.7. Effect of age on post-stroke respiratory activity
Age is an independent predictor of poor outcomes as older individuals have
both higher in hospital mortality and worse functional and cognitive outcomes
following an ischemic event. (122) Age may also affect the SIRD phenotype we
observed in young mice. Therefore, we performed a comprehensive assessment of
the effects of age on respiratory physiology in stroke and sham mice. On day 3-post
surgery aged male mice that underwent MCAO display decreases in both respiratory
frequency (243.5±29.6 vs. 185.3±12.4bpm, p<0.05, Fig. 3.7a) and minute ventilation
(2.5±0.3 vs. 1.1± 0.15 ml/g/min p=0.001, Fig. 3.7b&c), indicators of hypoventilation.
Although blunted, the ventilatory response to CO2 was unchanged, p=0.21, data not
shown. The incidence of apneas did increase following stroke (2.8±0.8 vs.
9.25±1.37, p<0.01, Fig. 3.7d). There was an effect of stroke on the ventilatory
response to hypoxia (p=0.05, Fig. 3.7e), although the chemosensitivity to hypoxia
remained unchanged, p=0.68, data not shown.
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Figure 3.7. Respiratory parameters of post-MCAO in aged males. The
respiratory phenotype of aged males (18-20 months) at day 3 that underwent MCAO
is similar to young males. Respiratory frequency is decreased, 243.5±29.6 vs.
185.3±12.4, p<0.05 (A) resulting in diminished minute ventilation under room air
conditions, 2.5±0.3 vs. 1.1± 0.15 ml/g/min p=0.001 (B). The ventilatory response to
CO2 is significantly blunted across all tested conditions, suggesting that aging is a
contributing factor limiting the system’s ability to respond to changes in ABG.
Interestingly, at day 3 the incidence of apneas increased significantly, 2.8±0.8 vs.
9.25±1.37, p<0.01 (D). Stroke also had a strong effect on the ventilatory response to
hypoxia, p=0.05 (E).
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3.8. Effect of sex on stroke induced respiratory dysfunction.
Stroke is a sexually dimorphic disease, with women having a lower incidence
of stroke in the age group of 55-75, until the age of 85 when women have a higher
incidence. (123, 124) Elderly women are disproportionally affected by stroke, having
higher age specific mortality and worse post stroke outcomes. (125) The majority of
human studies report an age dependent blunting of hypoxic and hypercapnic
ventilatory responses. (126, 127) However, there is conflicting evidence regarding
sex-associated change in the control of breathing. (128, 129) Sleep apnea has a
higher prevalence among men at all ages especially in elderly men who have a
higher incidence of all forms of sleep apnea: central, mixed and obstructive. (130)
Interestingly, elderly females with sleep apnea exhibit increased white matter loss
and changes in structural integrity in several brain regions compared to agematched males. (131) The incidence of SIRD as well as morbidity and mortality has
never been evaluated on the basis of sex.
To investigate sex differences in respiratory dysfunction following stroke we
subjected age 18-20 month old female mice to MCAO and assessed respiratory
parameters on day 3 post stroke. Minute ventilation was decreased in stroke mice
on day 3, sham 2.481±0.2179 vs. 1.849±0.1602 ml/min/g, p=0.03(A). Yet, there was
no increase in the incidence of apneas, sham 0.6±0.6 vs. 1.778±0.49 apneas/min,
p=0.16 (B). Aged female mice had higher baseline minute ventilation across all air
conditions compared to age males, room air females 2.729±0.18 vs. 2.22±0.07
ml/min/g, p<0.05 (C). Aged males displayed a greater percent change in minute
ventilation from baseline following stroke, males 52.66±3.25% vs. 30.22±3.1%
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p<0.001 (D). Metabolic demand, as measured by consumption of O2, was higher in
females accounting for increased levels of minute ventilation in comparison to agematched males, females 72.79±13.28 vs. 55.19±4.68 males, effect of sex p=0.01, 2way ANOVA. (E). Stroke did not affect metabolic activity in neither males nor
females. This does not explain the greater change in minute ventilation experienced
by males post stroke than females.

Variations in infarct did not account for the

discrepancies in minute ventilation observed between the sexes, day 7 % cerebral
atrophy male 17.07±8.91% vs. 24.22±4.65%, p=0.44 (F).
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3.8. Effect of sex on stroke induced respiratory dysfunction. Aged female mice
undergoing MCAO display a decrease in minute ventilation on day 3 following
surgery, sham 2.481±0.2179 vs. 1.849±0.1602 ml/min/g, p=0.03 (A). Despite having
no increase in the incidence of apnea, sham 0.6±0.6 vs. 1.778±0.49 apneas/min,
p=0.16 (B). At baseline aged females display an higher minute ventilation under
room air conditions and in response to hypercapnia, room air females 2.729±0.18
vs. 2.22±0.07 ml/min/g, p<0.05 (C). Aged males displayed a greater percent change
in minute ventilation from baseline following stroke, males 52.66±3.25% vs.
30.22±3.1% p<0.001 (D). Metabolic activity was increased in females compared to
males at baseline, females 72.79±13.28 vs. 55.19±4.68, 2-way ANOVA effect of sex
p=0.01, whereas stroke had no effect on metabolic activity in either sex (E).
Variations in infarcts did not account for the discrepancies in minute ventilation
observed between the sexes, male 17.07±8.91% vs. 24.22±4.65% atrophy, p=0.44
(F).
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3.9. Discussion.
We found that ischemic stroke induced by a transient 60 minute MCAO
produced respiratory dysfunction characterized by apneas and hypoventilation in
both young and aged male mice.

This recapitulates the respiratory phenotype

observed in human stroke patients. Stroke mice displayed a decrease in respiratory
frequency as well as an increase in the incidence of apneas resulting in a blunted
minute ventilatory response. This state of hypoventilation results in systemic hypoxia
and hypercapnia as measured by ABG, reconfirmed by periodic desaturations in
SpO2. ABG and SpO2 measurements were performed on day 3-post surgery during
the acute phase of post stroke recovery. Our long-term studies, (see Chapter 4),
found that apneas persist in mice up to 6 weeks following surgery. Weekly ABG
measurements following mice over this time period would further the understanding
of the magnitude of chronic apneas. Apneas and systemic hypoxia can have far
reaching consequences. In models of OSA, apneas produce arousals and
fragmented sleep. Experimental evidence utilizing chronic intermittent hypoxia found
amplified sympathetic response contributing to a hypertensive state. (132, 133) With
further consequences resulting in cellular stress promoting white matter loss and
axonal injury in brain regions such as the hippocampus.
Taken together, this suggests that the respiratory phenotype following stroke
is not a physiological compensatory response to changes in metabolic activity. Tidal
volumes in stroke mice do not decrease, but actually increase slightly compared to
sham, possibly as a compensatory mechanism in an attempt to maintain minute
ventilation. Implying that stroke induced hypoventilation is not a result of paralysis or
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paresis. Understandably, as direct brainstem lesions result in respiratory dysfunction
we wanted to rule out neuronal brainstem cell death as a contributing factor to
disordered breathing. MCAO does not result in any observable brainstem cell death
or degenerating neurons as assessed by TTC or Fluorojade staining. Unfortunately,
this does not rule out withdrawal of excitatory input from higher-level neuronal
circuitry disrupting respiratory neuron function.
Respiratory constancy relies on a delicate balance of chemoreceptor gain,
plant gain and temporal control of brain/heart blood flow. The Cheyne-Stokes
respiratory pattern observed in humans is proposed to be a result of the gaining up
of the chemoreflex. In this model of SIRD the slope of the ventilatory response to
CO2 remains unchanged, suggesting that chemoreceptor gain is not perturbed
following MCAO in an in-vivo whole body respiratory assessment. To further confirm
this electrophysiology techniques must be employed to assess the chemosensitivity
of varying neuronal respiratory control sites. Electrophysiology studies will also allow
for the interrogation of respiratory rate control neuron populations,.
The ventilatory response to hypoxia was explored by exposing mice to 10%
O2 environment. MCAO blunts the ventilatory response to hypoxia, yet the
chemosensitivity of this system was not affected. Suggesting that the intrinsic ability
of the neuronal populations responsible for detecting hypoxia remain intact, yet the
output of these groups is altered. Time delays in circulating blood gases between
lungs and chemoreceptor populations may contribute to this blunted response. This
may be due to local or systemic alterations in vascular reactivity or cardiac
variability. Local variations in astrocyte reactivity, basement membrane restructuring
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and fibrosis are potential candidates for disrupted neural vascular communication.
Decreases in respiratory activity may be indirectly altered by stroke. O2
consumption as a measure of metabolic activity was not altered by ischemic stroke.
Taken in consideration with our other findings this suggests the ischemic stroke
decreases basal respiratory activity in the presence of either hypoxia or
hypercapnia, while also increasing the incidence of apneas. This culminates in a in
a cyclic feed forward loop of respiratory dysfunction.
Since >80% of strokes occur in individuals over the age of 65(2), the aging
population bears the major brunt of stroke related mortality and disability. (122) It is
critical to investigate the mechanisms underlying stroke induced mortality and
functional/cognitive deficits. Surprisingly, our lab has found that although aged male
mice have less histological injury, they have significantly higher mortality and
functional deficits than their young counterparts. (134, 135) We performed a
comprehensive assessment of the effects of age on respiratory physiology in stroke
and sham mice.
Aged male mice display a higher level of respiratory activity, reflective of an
increase in minute ventilation (normalized to body weight), which may be explained
by changes in metabolic activity that accompany aging. The SIRD phenotype
witnessed in aged males was similar to that of young. They displayed a decrease in
respiratory frequency, a blunted minute ventilatory response to both hypercapnia
and hypoxia, with no changes to chemosensitivity. Aged males also suffer from an
increase in apneas during respiratory assessments conducted during the acute
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phase of ischemia. Collectively, the stroke induced respiratory phenotype is similar
regardless of age in males. At baseline aged females display an increased minute
ventilation under room air conditions compared to males, which is explained by
increased metabolic activity. Interestingly, aged females have a less pronounced
disordered breathing phenotype despite having similar sized infarcts as aged males.
This may partly explain why aged male mice have worse functional outcomes and
higher post stroke mortality than females. The hormonal and chromosomal
contributions to sex differences in stroke are an area of ongoing investigation.

For

example, ischemia induced astrocyte reactivity is differentially regulated by age and
sex. Increased levels of IL-6, IL-1b and TNF-α were observed in aged male
astrocytes compared to astrocytes derived from females. (136, 137) There are likely
many mechanisms contributing to the sex based variations in respiratory dysfunction
following ischemia. The long-term consequences of apnea may differ greatly based
on the age and sex of the animal, and this may contribute to increased mortality and
worse outcomes following ischemia.
3.10. Future Directions.
We identified and characterized a stroke induced disordered breathing model
in mice characterized by hypoventilation and apneas, resulting in systemic hypoxia.
Recapitulating the breathing phenotype observed in the human population suffering
from stroke. To further understand how stroke disturbs respiration, cellular electrical
properties of major respiratory central chemoreceptor sites such as the NTS and
RTN, as well as rate control sites (Botzinger and pre-Botzinger complex) should be
examined. Intrinsic characteristics such as resting membrane potential, basal firing
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rate and chemosensitivity must be studied to completely understand how stroke
induces respiratory dysfunction.
Before we can conclude that disordered breathing is strictly a result of a
decrease in basal respiratory activity the other components of loop gain must be
evaluated. MCAO may have direct effects on cardiac output and rhythmicity. Cardiac
instability could contribute to time delays in circulation between the lungs and
chemoreceptors. Implantable telemetry can be employed to monitor changes in
blood pressure and EKG variability. To further corroborate these findings
measurements of arterial CO2 and O2 should be collected from the pulmonary vein
and the entrance of the brain to assess time delays between heart/lung and brain
tissue. Lastly, the apneic threshold in mice may be perturbed following stroke.
Utilizing mechanical ventilation and diaphragmatic electromyography (EMG) as
previously described(138); alterations to CO2 apneic threshold can then be
addressed under steady state conditions.
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Chapter 4. The Severity of Respiratory Dysfunction
Correlates with Progressive Cognitive Decline.
Rationale: Patients suffering from stroke induced respiratory dysfunction display
signs of progressive cognitive decline for years following stroke. To determine if
MCAO induced respiratory dysfunction produces cognitive decline, we performed
longitudinal studies to evaluate the progression of respiratory parameters and
cognitive outcomes over a six-week period.

4.1. MCAO results in progressive cognitive decline.
Sham and stroke mice underwent cognitive assessment utilizing the Barnes
maze on days 21 and 42 post surgery. On day 21-post surgery stroke mice take
longer to find the escape hole than sham (stroke 53.26±8.45 seconds vs. sham
21.04±2.6, p<0.01, Fig. 4.1a). On day 42-post surgery stroke mice again perform
worse than sham in both escape time (stroke 95.02±26.75 seconds vs. sham
22.83±6.72, p<0.05) and total errors made prior to finding escape hole (stroke
50.91±9.5 vs. sham 15.2 ±5.7, p=0.01, Fig. 4.1b). More importantly stroke mice
performed worse on day 42 than on day 21, taking longer to escape and making
more total errors (day 21 25.8± vs. day 42 50.91±9.5 errors, p=0.01), suggestive of
progressive cognitive decline. Coinciding with these findings stroke mice perform
worse on the Novel Object Recognition Test and in Contextual Fear Conditioning.
Stroke mice spend dramatically reduced time with the novel object compared to
sham on day 28 (2.51±0.7 vs 1.29±0.19 ratio of time (s), p<0.05, Fig. 4.1c). On day
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42, stroke mice display less freezing behavior compared to sham in fear conditioning
arena (65.49±6.87% vs 48.91±3.6, p<0.05, Fig. 4.1d).
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Figure 4.1. MCAO results in cognitive decline. During Barnes maze testing stroke
mice take longer to find escape hole on day 21 than sham (stroke 53.26±8.45
seconds vs. sham 21.04±2.6, p<0.01) indicative of cognitive impairment, stroke n
=11, sham n=6. Barnes maze assessment on day 42 post surgery stroke mice again
perform worse than sham, increasing the time to find the escape hole compared to
day 21, stroke 95.02 ± 26.75 seconds vs. sham 22.83 ± 6.72, p<0.05 (A).
Interestingly, on day 21 stroke mice make approximately the same number of errors
as sham, yet on day 42, stroke mice not only make more errors than sham but more
errors than they did on day 21, suggesting progressive cognitive decline (stroke
50.91±9.5 vs. sham 15.2 ±5.7, p=0.01) (B). Findings of day 28 NORT also are
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indicative of cognitive decline, stroke mice spend less time with the novel object in
relation to the familiar object when compared to sham, 2.51±0.7 vs 1.29±0.19 ratio
of time (s), p<0.05 (C). Lastly, stroke mice spend less time displaying freezing
behavior during contextual fear condition on day 42, 65.49±6.87% vs 48.91±3.6,
p<0.05, n=11 and n=6 respectively (D).
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4.2. Evolution of stroke induced respiratory dysfunction.
Following plethysmography assessment on day 42-post surgery, we found
that stroke mice can be stratified into two groups based on the number of apneas
per minute. The minor group presented with 5 or less apneas a minute, while the
severe group had 5 or more apneas a minute, representative plethysmography
waveforms shown (Fig. 4.2a). The determination to separate groups based on the
number of apneas a minute was adapted from American Academy of Sleep
Medicine criteria used in humans. (75) The respiratory pattern of the severe group is
indicative of Cheyne-Stokes patterned breathing, marked by waxing and waning of
tidal volume followed by periods of apnea, representative waveforms (Fig. 4.2c).
Consistent with day 3 findings, we find no indications of alteration in
chemosensitivity as measured by the ventilatory response to CO2, p= 0.51 (Fig.
4.2b).
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Figure 4.2. Evolution of the SIRD phenotype. On day 42 post surgery, stroke mice
can be stratified into 2 groups based on the number of apneas a minute. The minor
group experience 5 or less while the severe group suffers 5 or more apneas a
minute (A). The central chemosensitivity did not differ between the minor or the
severe groups, p=0.51 (B). Representative waveforms of the minor and severe
groups on day 42 post surgery, n=7 respectively (C). The waveform of the severe
group is indicative of the Cheyne-Stokes respiratory pattern, marked by waxing and
waning of tidal volume followed by apnea.
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4.3. Progressive cognitive decline correlates with the severity of disordered
breathing.
After stratifying stroke mice based on the severity of respiratory dysfunction
cognitive functions were reevaluated based on this criteria. Surprisingly, we found
that mice that suffer severe form of disordered breathing display signs of progressive
cognitive decline while those with minor apneas, do not. Performance on Barnes
maze was consistent with progressive cognitive decline (Fig. 4.3). There is an effect
of time on total errors made in the stroke group as a whole (D21 vs D42, p=0.01,
n=7 Fig. 4.3a). Interestingly, multiple comparisons analysis revealed that animals
with the most severe disordered breathing made more errors on day 42 (D21
28.3±13.1 vs. D42 70±21.6 errors, p=0.05, Fig 4.3a). Again, on Barnes maze there
was an effect of time to escape hole in the stroke cohort as a whole (D21 vs. D42,
p<0.05). Multiple comparison analysis exposed the severe group to have increasing
escape time (D21 86.96±36.3 seconds vs. D42 217.9±82.1, p=0.05, Fig. 4.3b).
These findings were consistent during contextual fear conditioning.
Mice with the most severe disordered breathing display less freezing behavior
in fear conditioning arena on day 42 post stroke (Minor 47.1±2.1 secs vs. severe
35.8±4.8 secs. P<0.05) (Fig. 4.3c.). Linear regression analysis of percent time
freezing compared to the number of apneas a minute, found a significant non-zero
slope (p<0.05), indicating a negative correlation between apneas and freezing
behavior. (Fig. 4.3d)
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Figure 4.3 Progressive cognitive decline correlates with the severity of SIRD.
Barnes maze performance was similar on day 21 between the minor and severe
groups on time to escape and number of errors made. On day 42-post stroke, the
minor group is consistent in their performances on day 21. The severe group on the
other hand not only takes longer to find the escape hole (D21 86.96±36.3 seconds
vs. D42 217.9±82.1, p=0.05), but also makes more errors than they did on day 21
(D21 28.3±13.1 vs. D42 70±21.6, p=0.05, n=7), (A & B). During contextual fear
condition testing, the severe group displays less freezing behavior than the minor
group suggesting cognitive impairment, (minor 47.1±2.1 secs vs. severe 35.8±4.8
78

secs. P<0.05) (C). Linear regression analysis found a negative correlation between
the number of apneas and cognitive performance measured as freezing time during
contextual fear conditioning test, p<0.05 (D).
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4.4. Variations in stroke severity do not define the severity of respiratory dysfunction.
To rule out variation in infarct variability amongst the two groups of disordered
breathing we assessed cerebral atrophy and day 3 post stroke assessments. No
differences were observed in measurements of cerebral atrophy between the minor
and severe groups after sacrifice on day 42, p=0.66. NDS, p=0.19. Corner test, a
measurement of sensory motor function were the same for both groups of mice
when they were assessed at day 3-post stroke, p=0.75 (Fig. 4.4).
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Figure 4.4. Variations in stroke severity do not define the severity of
respiratory dysfunction. No differences in volume of cerebral atrophy were found
at day 42 post stroke between the minor and severe groups of disordered breathing,
p=0.66 (A). Neurological deficit scores at 1 hour following ischemia and day 3 post
stroke were identical between the two groups, p=0.19, n=7 (B). Functional
outcomes, measured by the corner test, at day 3 (p=0.75) and 7-post stroke
(p=0.23) were similar amongst the groups (C).
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4.5. Distal MCAO does not produce disordered breathing or cognitive decline.
Distal MCAO was employed to determine if a smaller cortical infarct produces
disordered breathing or cognitive decline in a similar manner to MCAO.
Plethysmography assessment on days 3, 21 or 42-post surgery found no indications
of disordered breathing, hypoventilation, p=0.97, or apneas, p=0.77, day 3 data
shown (Fig. 4.5a and 4.5b). Cognitive performance, assessed by Barnes Maze,
p=0.7, and NORT, p=0.56, was found to be unremarkable between stroke and sham
groups (Fig. 4.5).
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Figure 4.5. Distal MCAO does not result in disordered breathing or cognitive
decline. Mice undergoing dMCAO do not develop respiratory dysfunction evident by
no change in minute ventilation, p=0.97 (A) or absence of apneas, p=0.77 (B). Sham
and stroke mice had similar escape times on Barnes maze on day 42, p=0.7, n=6
(C). Both groups of mice showed a preference for the novel object, indicative of no
deterioration in cognitive performance, p=0.56 (D).
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4.6. Discussion.
Our six-week studies reproduced findings of many studies reporting cognitive
deficits following ischemic stroke. (139, 140) Cognitive deficits following MCAO may
be detected as early as 3 days following ischemia and persist for months in rodents
and for years in humans. (141) Human studies have one additional prominent
finding; they report signs of persistent cognitive decline over many years following
stroke. Our current study found indications of progressive cognitive decline in spatial
learning and memory, a hippocampal dependent task, over a six-week period
following MCAO. The hippocampus receives blood supply via the anterior choroidal
artery and the posterior communication artery(142), both of which are unaffected by
MCAO. This suggests that other factors are contributing to post stroke cognitive
decline such as inflammation, disordered breathing and hypoxia.(143)
During the course of six weeks mice underwent weekly plethysmography
studies to assess respiratory function post stroke. To our surprise we discovered
that mice could be divided into one of two groups based on the number of apneas
per minute. This criteria is similar to the Apnea-Hypopnea Index (AHI) used in
humans to report the number of apneas an hour during sleep. Mice were stratified as
either minor (less than 5 apneas a minute) or severe (10 or more apneas a minute).
Respiratory tracings from mice in the severe group represent a Cheyne-Stokes like
form of periodic breathing, with a waxing and waning of tidal volume. While the
minor group displays a relatively stable respiratory pattern, displaying improvements
from day 3 tracings. The slope of the ventilatory response to CO2 remains
unchanged in either group, consistent with our previous findings, suggesting no
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change in chemoreception. The variations in tidal volume in the severe group
suggest it is the effects of ventilation on blood gases that may be contributing to the
development of apneas in mice. Respiratory chemoreceptors contribute to both
respiratory rate and tidal volume based on stimulus of CO2/H+, the increases in tidal
volume on a breath to breath basis eliminate larger volumes of CO2, decreasing the
CO2 reserve until CO2 levels drop below apneic threshold resulting in apnea. We can
infer that CO2 levels begin to drop by the decreases in tidal volume observed in the
one or two breaths preceding an apnea. Increases in plant gain are predicted to
destabilize breathing by decreasing the CO2 reserve. Breath by breath
measurements of tidal volume and exhaled CO2 will confirm our conclusions that
MCAO increases plant gain therefore destabilizing breathing.
Based on our respiratory findings, we performed a post hoc analysis of
cognitive function based on our assigned apnea criteria. Surprisingly, only mice with
a severe form of disordered breathing suffer from progressive cognitive decline. Both
groups had similar outcomes in the number of errors made prior to finding the
escape hole, as well as time to find the escape hole on Barnes Maze at a 21-day
time point. In contrast, on day 42 the severe group made more errors prior to finding
the whole and took longer than the minor group. More importantly, performance on
day 42 was worse than day 21 within the severe group, indicative of progressive
cognitive decline. The minor group displayed similar performance on both days 21
and 42.
Freezing behavior measured on contextual fear conditioning arena, an
amygdala-hippocampal associative learning task, found that the severe group
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displayed less freezing behavior than the minor group. We also found a negative
correlation between the number of apneas per minute and percent time freezing,
indicative of a relationship between the severity of disordered breathing and
deteriorating cognitive function.
Although studies in human patients found no association between stroke size
or location and the development of disordered breathing, we wanted to assess the
effect of stroke size on the development of disordered breathing. Differences in
cerebral atrophy volumes between the two groups at day 42 was negligible. We also
found no histological indications of posterior hemisphere or brainstem infarction.
NDS measured at the time of ischemia and on day 3 were identical between animals
in both groups. Corner test, a measure of functional disabilities, again was identical
between animals of both groups on day 3 and 7. Taken together, we conclude that
variation in stroke severity does not impact the development of disordered breathing.
Lastly, we employed the distal MCAO model to determine if a small stroke
limited to the cortex produced disordered breathing or cognitive decline. When
followed for a six week time period no detectable differences were noted between
stroke and sham groups in any of the respiratory parameters previously assessed.
We did not find any evidence of cognitive decline on either Barnes Maze or NORT.
These findings are important for two reasons. First the mechanism by which stroke
induces disordered breathing is not initiated or sustained in a smaller, cortical stroke.
Until we have a better understanding of the mechanism(s) underlying the
development of disordered breathing the use of the distal model to rule out stroke as
the primary contributor to progressive cognitive decline is limited. Second, a single
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cortical stroke does not result in cognitive decline, suggesting that disordered
breathing is a factor in contributing to progressive cognitive decline witnessed in
MCAO mice.

4.7. Future Directions.
To better understand the role of disordered breathing, namely apneas, in the
development of progressive cognitive decline steps must be taken to separate other
possible contributions induced by ischemic stroke. Currently, animal models of
disordered breathing are not well equipped to answer this question. Models inducing
central apneas are not specifically targeted to disrupt only breathing such as whole
animal monoamine oxidase-A knock out mouse. (144) Recently, a GPR4 channel
was determined to be a major chemosensing mechanism of RTN neurons, and
lentiviral knock down of this protein produced hypoventilation and an increase in the
incidence of apneas. (46) GPR4 knock out mice are available but come with many
downfalls, such as decreased litter size, spontaneous hemorrhage and altered
kidney function. The development of an inducible Phox2b Cre floxed GPR4 mouse
line would avoid many of these issues. An inducible line would bypass any potential
detrimental outcomes in knocking out this protein during development while limiting
the knockdown of GPR4 to Phox2b positive neurons such as the RTN and NTS.
This KO line would allow for further assessment of apneas role in progressive
cognitive decline.
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Chapter 5. Brainstem reactive gliosis and the role of TGF-B
Rationale: Evidence from our previous studies suggests that hemispheric stroke
does not result in direct brainstem neuronal cell death to produce disordered
breathing. With this in mind we began to explore other cell types as possible
contributors to disordered breathing. As we began our investigation a study was
published determining that intracerebroventricular (ICV) injections of streptozotocin
not only induced blunted respiratory response but also produced reactive gliosis
surrounding many key respiratory control centers such as the NTS and preBotzinger complex. (145) This suggests that there is a pathway of communication
from the cerebral hemispheres to the brainstem that may be transmitted via CSF
and provides evidence that glia cells may be contributing to respiratory dysfunction.
TGF-B expression increases following ischemic stroke leading to reactive
astrogliosis in infarct area. We explore this as a possible mechanism of stroke
induced respiratory dysfunction.

5.1. MCAO results in pronounced brainstem astrogliosis.
GFAP staining of young and aged brainstem slices revealed a pronounced
astrogliosis in brainstem areas of the NTS and ventral medullary surface (VMS)
young shown, a region containing RTN neurons (average # cells/field of view VMS:
47.67±4.33 vs. 94±11.15, p<0.05, NTS: 13±3.78 vs. 125.7±31.6, p<0.05, Fig. 5.1).
This reactive gliosis is evident as early as day 3-post stroke and remains present on
day 21 and day 42.
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Figure 5.1. MCAO induces pronounced

astrogliosis surrounding key

brainstem respiratory neuronal populations. 20x view of GFAP IHC staining of
brainstem slices from day-3 post stroke mice revealed a pronounced astrogliosis in
the VMS and NTS compared to sham, average # cells/field of view VMS: sham
47.67±4.33 vs. 94±11.15, p<0.05, NTS: sham 13±3.78 vs. 125.7±31.6, p<0.05 (A).
Schematic included showing geographical location of these sites. GFAP + cell
counts were significant in both regions compared to sham (B & C).
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5.2. ICV injection of TGF-B produces disordered breathing and reactive gliosis in the
brainstem.
ICV injections of TGF-B into the lateral ventricle of naïve mice produced
respiratory dysfunction characterized by hypoventilation (minute ventilation room air
2.076±0.008 vs. 1.157±0.07 ml/g/min, p<0.001, Fig. 5.2b) and an increase in
apneas compared to saline injected animals (1.3±0.3 vs. 5.6±1.6, not significant
p=0.06, Fig. 5.2c) on day 1. Brainstem IHC analysis revealed a pronounced
astrogliosis compared to vehicle in areas of the NTS and VMS (Fig. 5.2d).
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Figure 5.2. ICV TGF-β injections induce altered respiratory activity and
brainstem astrogliosis. 2mm brain slices following Evan’s Blue ICV injection into
cerebrospinal fluid. Lateral ventricle injection diffuses throughout CSF compartments
(A). On day 1 following injection mice display blunted minute ventilation,
2.076±0.008 vs. 1.157±0.07 ml/g/min, p<0.001, n=3 (B) as well as an increase in
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the incidence of apneas, 1.3±0.3 vs. 5.6±1.6, not significant p=0.06 (C). IHC
performed on tissue day 7-post injection revealed pronounced astrogliosis in
brainstem regions of respiratory control (D).
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5.3. TFG-B signaling in brainstem astrocytes increases following MCAO.
Increases in TGF-B1 expression following stroke are proposed to be
neuroprotective while other isoforms enhance glial reactivity obstructing recovery,
but have only been assessed in the peri-infarct region following stroke. (85) We
performed IHC using pSmad2, a downstream component of the TFG-B signaling
cascade, to assess both increases in TGF-B signaling as well as evidence of colocalization with reactive astrocytes. On day 3 post surgery increases in GFAP
immunoreactivity were observed in stroke mice compared to sham as previously
reported. pSmad2/GFAP co-localization was increased in stroke tissue, although it
only accounted for a small number of GFAP positive astrocytes (0.33±0.33 vs.
5.4±1.3, p<0.01, Fig. 5.3c). Representative images shown of 20x and 63x views
(Fig. 5.3a and b). Total pSmad2 signaling in brainstem regions was unaffected by
MCAO as measured by IHC, data not shown. N=3 animals per group, 2 slices per
animal.
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Figure 5.3. TGF-β signaling increases in the brainstem following MCAO.
pSmad2 immunoreactivity, indicative of TGF-β signaling, was co-localized with
astrocytes on day 3 following MCAO, 20x images shown (A), 63x image, arrows
indicating colocalization of GFAP and pSmad2. (B). Quantification of pSmad2/GFAP
co-localization quantified, sham 0.33±0.33 vs. 5.4±1.3, p<0.01 (C). pSmad2-green,
GFAP-red, Dapi-blue.
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5.4. Distal MCAO does not result in brainstem astrogliosis.
To understand if brainstem reactive gliosis is unique to MCAO we performed
GFAP IHC on brainstem slices of mice that underwent distal MCAO. We found no
indications of reactive gliosis as evident by GFAP immunofluorescence in distal
MCAO or sham mice, sham 20.67±10.88 vs. 19.33±1.76, p=0.53 (Fig. 5.4).

Figure 5.4. dMCAO does not up regulate GFAP expression in the brainstem.
No measureable differences in the level of GFAP expression in the regions of NTS
or VMS following dMCAO, sham 20.67±10.88 vs. 19.33±1.76, p=0.53. N=3 animals
per group, 2 slices per animal.
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5.5. Discussion:
MCAO induces a multifaceted, progressive inflammatory response affecting a
variety of cells both locally and systemically. Following ischemia, injured or dying
neurons, astrocytes, microglia or endothelial cells release components containing
damage associated molecular patterns (DAMPs), triggering innate immune
activation and production of numerous cytokines including IL-6, IL-1, TNF-α and
TGF-β. (85, 146, 147) These cytokines induce systemic responses inducing
reactivity in both bone marrow and the spleen. We considered whether MCAO
induced an inflammatory response in the brainstem contributing to respiratory
dysfunction. IHC analysis of serial slices of brainstem tissue revealed pronounced
astrogliosis, markedly in the region of the VMS, 4th ventricle and NTS. This reactive
gliosis was evident on day 3 and persisted through day 42-post stroke. It is worth
noting that GFAP immunoreactivity is the current hallmark of astrocyte reactivity and
that its detection may be extremely limited in quiescent astrocytes. (64) As the
contributions of astrocytes to respiratory activity are continuously being investigated,
this finding is conceivably an indicator of how stroke disrupts breathing. Brainstem
astrogliosis may disrupt breathing via many mechanisms not limited to: basement
membrane fibrosis, purinergic control of vascular tone or stimulation to neuronal
activity. Alterations in basement membrane fibrosis may inhibit both neuronal and
astrocyte detection of CO2/H+. The latter two will be discussed in the following
chapter.
In the peri-infarct region following stroke, astrocytes play a major role in
extracellular matrix remodeling and glial scar formation by secreting numerous
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proteins including laminin and fibronectin. (148) The presence of these molecules
along with glial scar formation contributes to inhibition of neural regeneration and
communication into the injury site. Numerous factors including context dependent
signaling and distance from lesion influence the degree of astrocyte reactivity and
alterations in gene profile. It is not possible to equate GFAP reactivity with a single
unique astrocyte profile. (149)
A number of cytokines are up regulated following stroke that can induce
astrocyte reactivity such as TGF-β. Increases in astrocyte TGF-β signaling following
stroke have been recently demonstrated. (85) As others have shown ICV injections
of other compounds, such as Streptozatocin, induces respiratory dysfunction and
brainstem astrogliosis. (145) To explore this signaling mechanism TGF-β ICV
injections were performed in naïve mice. To our surprise, respiratory parameters
were blunted by TFG-β injection on day 1 and persisted for a week in a similar
fashion following MCAO. GFAP staining of these tissues additionally demonstrated a
pronounced reactive astrogliosis in the brainstem. This indicates that CSF-perfused
TGF-β induces astrocyte reactivity in the brainstem as well as producing respiratory
dysfunction. Total levels of brainstem pSMAD2, indicative of TGF-β signaling, were
not increased following MCAO at day 3 or 21 in the brainstem. Only accounting for a
small percentage of reactive astrocytes, co-labeling of pSmad2/GFAP was
increased in stroke animals on day 3. Albeit a small one, this suggests that TGFβ/Smad2 signaling plays a role in astrocyte activation. While phosphorylation of
Smad2 has been accepted as marker of TGF-B signaling in astrocytes, most likely
as a neuroprotective signal, it fails to account for any contribution of Smad3
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signaling. Ablation of Smad3 signaling reduces inflammation, gliosis, and fibronectin
deposition in the weeks following injury. (150, 151) Numerous inflammatory
cytokines, many of which are up regulated following ischemic stroke, can induce
astrocyte reactivity and should be explored to further understand post stroke
brainstem gliosis. Neuroinflammation activates the Jak2-Stat3 signaling pathway
prior to the up regulation of GFAP. (152) Conditional astrocyte Stat3 knockout mice
attenuated astrogliosis in a model of MPTP neurotoxicity(153) and could be utilized
to understand if astrogliosis induces respiratory dysfunction following MCAO.
Previously, we have shown that dMCAO produces neither disordered
breathing nor cognitive decline. IHC analysis of brainstem tissue revealed no
differences in GFAP immunoreactivity between dMCAO stroke and sham mice,
further supporting a strong a contribution of astrogliosis to disordered breathing.

5.6. Future Directions.
Our experimental findings demonstrate a pronounced astrogliosis in major
sites of brainstem respiratory control, as evident by increased GFAP expression.
Although understood to be a marker of reactive astrocytes, GFAP expression is not
indicative of a beneficial or detrimental role of astrocytes. At this time we are
unaware if this reactivity disrupts normal astrocytic functions in respect to respiratory
control. A cytokine profile of CSF and brainstem tissue may provide insight to what
molecules are potentially activating brainstem astrocytes. Yet, those findings may
denote numerous molecules are contributing to a reactive phenotype. Many proinflammatory cytokines converge on the same signaling pathway, providing a more
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strategic target. The p38 MAPK pathway is activated by numerous pro-inflammatory
cytokines(154) and plays an important role in ischemic stroke induced gliosis.
Inhibition of this pathway reduced glial scar formation without affecting infarct
volumes or functional outcomes when measured 4 days after stroke. (152) It would
be interesting if overexpression of p38 MAPK or Jak2-Stat3 in astrocytes induces
respiratory dysfunction. Furthermore, inhibition of these pathways following MCAO
should be explored as potential therapeutic targets to prevent SIRD.
Further experimentation must be performed to understand the relationship
between TGF- β induced astrogliosis and disordered breathing. We our currently in
the process of crossing a floxed TGF- β receptor to an inducible GFAP cre line
resulting in an astrocyte specific TGF- β receptor knockout mouse. The inducible
feature of this animal model allows for temporal control of TGF-β knockout.
Assessments of gliosis and disordered breathing will be obtained following the ICV
administration of TGF- β. We anticipate that this animal model will further our
understanding of the role of gliosis in the development of disordered breathing.
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Chapter 6. Pharmacological stabilization of respiratory
activity to improve cognitive outcomes.
Rational: Clinical evidence suggests respiratory dysfunction slows recovery and
contributes

to

increased

mortality.

For

example,

although

CPAP

is

not

recommended for treatment of central apneas and is poorly tolerated by elderly
patients, it has been shown to enhance neurological recovery in some stroke
patients thus underscoring the importance of normal respiratory function in stroke,
and suggesting treatments targeting respiratory dysfunction can improve post-stroke
recovery. Consistent with these clinical observations, preliminary evidence in male
mice show that stroke results in a respiratory phenotype in conjunction with other
behavioral deficits including functional disabilities, cognitive decline and a high
mortality rate. These results suggest ventilatory problems contribute to strokeinduced functional deficits and high mortality. To test this, we will evaluate the
efficacy of treatments designed to improve respiratory function on motor and
cognitive outcomes.

6.1. Administration of KCNQ agonist Retigabine destabilizes breathing.
In an effort to stabilize post stroke respiratory dysfunction we utilize the
KCNQ channel agonist Retigabine, to target RTN KCNQ channels. On day 3-post
surgery mice underwent plethysmography, followed by Retigabine (10mg/kg) or
DMSO vehicle SQ with subsequent plethysmography testing. Retigabine decreased
both respiratory frequency and minute ventilation in stroke and sham mice (data not
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shown). This was a result of increasing the interbreath interval as observed (Fig.6.1).
For 90% of the breaths taken in stroke mice, the time between breaths is 368ms or
less. Retigabine increases that interval to 468ms. Following these observations, we
hypothesized that XE991, a KCNQ channel antagonist previously shown to increase
basal activity of RTN neurons in vitro, would stimulate respiratory activity following
MCAO. XE991 (2mg/kg) or vehicle was administered to mice day 3-post surgery
with no detectable effect on any respiratory parameter, data not shown.
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Figure 6.1. Retigabine increases the interbreath interval further destabilizing
breathing. Retigabine (10mg/kg) administered on day 3-post surgery results in a
right shift of the histogram indicating increase in time between all breaths, expected
to further destabilize respiratory activity.
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6.2. Acetazolamide administration eliminates apneas.
Acetazolamide is known to enhance basal breathing by inducing metabolic
acidosis, commonly used to treat acute altitude sickness. Acetazolamide (40mg/kg)
or saline vehicle was administered SQ to mice on day 3 following surgery.
Acetazolamide increased respiratory frequency in stroke mice compared to vehicle
(152.6±6.49 vs. 318.4±61.95 bpm, p<0.05, Fig.6.2a) (Sham respiratory frequency
286.7±13.97). While concurrently decreasing the incidence of apneas (6±1.15 vs
0±0, p<0.01, Fig.6.2b). Representative respiratory tracings shown (Fig.6.2c).
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Figure 6.2. Acetazolamide increases respiratory frequency and eliminates
apneas. Acetazolamide increases the respiratory frequency of stroke mice,
152.6±6.49 vs. 318.4±61.95 bpm, p<0.05 (A), while also eliminating apneas under
room air conditions, 6±1.15 vs 0±0, p<0.01, n=3 (B). Representative waveform
tracings shown (C).
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6.3. Long-term administration of acetazolamide improves cognitive outcomes
following MCAO.
Acetazolamide (40mg/kg) or saline vehicle was administered over a four
week period beginning on day 14 following surgery via osmotically driven SQ
implanted Alzet pumps. Cognitive assessments performed on day 21 following
surgery detected no differences between the treatment groups, as a group stroke
mice perform worse on Barnes maze than sham, (Mantel-Cox test, p<0.001,
Fig.6.3a). On day 42 stroke mice treated with Acetazolamide had significantly
improved cognitive performance compared to sham (p=0.0005, n=6 per sham group,
n=11 per stroke group Fig. 6.3b). Upon sacrifice histological assessment of
hemisphere atrophy was conducted. There were no differences in cerebral
hemisphere atrophy between acetazolamide and saline vehicle administered stroke
groups, (sham 34.53±3.45 vs. 29.94±6.47, p=0.5, Fig. 6.3c).
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Figure 6.3. Continuous administration of Acetazolamide improves long term
cognitive outcomes following MCAO. Mice underwent spatial learning and
memory testing using the Barnes maze on day 21 and day 42-post surgery. On day
21 stroke mice as a group perform worse than sham, taking longer to locate the
escape hole, Mantel-Cox test, p<0.001 (A). On day 42 testing, acetazolamide
administered stroke mice show a marked improvement in their ability to locate the
escape hole when compared to vehicle-administered shams, p=0.0005 (B). No
variations in the severity of infarct between the two groups when hemispheric
atrophy was measured, sham 34.53±3.45 vs. 29.94±6.47, p=0.5 (C).
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6.4. Acetazolamide dilates cortical arteries while constricting brainstem arteries in
slice recordings.
Slices of brain tissue from naïve mice were collected to measure arteriole
vessel diameter in the cortices and brainstem under physiological conditions (5%
CO2 balanced air) and after application of Acetazolamide (500 um plus 5% CO2
balanced air). We reconfirmed that application of Acetazolamide dilated cortical
arteries

(mean of differences 0.5584±0.1303 µm, p=0.002, Fig. 6.4c and e).

Surprisingly, this effect was reversed in RTN arterioles, were we observed
constriction (-0.6089±0.1942 µm, p=0.0095, Fig. 6.4a and e).
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Figure 6.4. RTN and cortical arterioles differentially react in in vitro arteriole
slice recordings. (A) Diameter trace of an example RTN arteriole constricting in
response to bath application of 500 µm Acetazolamide. (B) An example RTN vessel
image profile plot with application of Acetazolamide, -0.6089±0.1942 µm, p=0.0095.
Profile plot scale bars: 2000 a.u., 10 µm. (C) Diameter trace of an example cortical
arteriole dilating in response to application of 500 µm Acetazolamide, mean of
differences 0.5584±0.1303 µm, p=0.002. (D) An example cortical vessel image
profile plot with application of Acetazolamide. Profile plot scale bars: 2000 a.u., 10
µm

(E) Summary data shows differential reactivity of Acetazolamide; a

vasoconstriction is seen in the RTN (N = 10 vessels) while a vasodilation is seen in
the cortex (N = 10 vessels)**, difference in µm from baseline (p<0.01).

111

6.5. Discussion and Future Directions.
Our earlier experimental results indicate that MCAO produces disordered
breathing in mice and that the severity of disordered breathing correlates with
worsening cognitive decline. With an understanding of brainstem respiratory
physiology we employed Retigabine in effort to improve respiratory instability while
eliminating apneas. Retigabine, a high affinity voltage gated potassium channel
(KCNQ) agonist, decreases membrane potential altering the firing rate of RTN
neurons in vitro. Referencing Figure 4.2c, we originally believed the burst of
respiratory activity (segments of waxing and waning of tidal volume) to be
problematic and by reducing the activity of RTN neurons (responsibility for both
respiratory frequency and tidal volume) would stabilize breathing and eliminate
apneas.
Retigabine had a depressive effect on respiratory activity in both stroke and
sham mice, while also increasing mortality in the stroke coort. By enhancing
potassium channel activity, Retigabine increased the breath-to-breath time interval,
reduced tidal volume while overall decreasing minute ventilation. Based on these
experimental outcomes, we hypothesized that XE991 (a KCNQ antagonist) would
have opposite effects by increasing respiratory activity. When administered
systemically we observed no effect on respiratory activity in either stroke or sham
mice. To rule out low dosage as the cause, 3mg/kg was administered, which
induced seizure like activity in sham mice. This finding does not come as a surprise
due to the KCNQ channel’s regulation of neuronal excitability. In summary, systemic
activation of KCNQ channels decreases respiratory activity.
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In subsequent experiments we demonstrate that the administration of
Acetazolamide to MCAO mice enhances respiratory activity while suppressing the
apneas. Continuous administration of Acetazolamide greatly improves long-term
cognitive outcomes. Lastly, in contrast with the observed and expected vasodilation
of cortical arterioles, we show that in vitro application of Acetazolamide to brainstem
slices from young male animals constricts arterioles of the RTN. This may provide
insight into the mechanism of how Acetazolamide enhances respiratory activity, and
how MCAO disturbs brainstem respiratory function. To address the later, similar
experiments must be performed in brainstem slices of MCAO and sham mice to
examine vascular responsiveness to changes in CO2. The concept of differential
regulation of vascular tone is not new to mammalian physiology. Unlike systemic
arterioles, which dilate in response to low levels of O2, pulmonary arterioles constrict
in a process referred to as hypoxic pulmonary vasoconstriction or pulmonary
shunting. (155) Although the precise mechanism underlying this phenomenon is still
be resolved, there is increasing evidence that suggests hypoxia stimulates a rise of
intracellular calcium in pulmonary artery smooth muscle culminating in vascular
constriction. (156) This concept must be considered when studying the physiology of
brainstem arterioles as well as the mechanisms in which stroke disrupts brainstem
processes producing disordered breathing.
It has been hypothesized that the Acetazolamide mediated increase in
respiratory activity following acute altitude sickness is in response to increase in H+
concentration. This increase in H+ can have a two-fold effect on respiratory activity.
First, an increase in H+/CO2 concentration would intensify central chemoreceptor
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stimulation, increasing respiratory activity, while concurrently expanding the CO2
reserve, stabilizing breathing. Second, acetazolamide decreases arteriole diameter
in the region of the RTN in a similar manner as increased H+/CO2, effectively
decreasing regional blood flow.
Alternatively, it is understood that vascular tone in the region of the RTN is
mediated in part by purinergic signaling. Previous evidence indicates RTN
astrocytes release ATP in response to increases in CO2/H+. Pharmacological
activation of RTN astrocytes reconfirmed this finding, while also demonstrating a
subsequent purinergic mediated arteriole constriction. To further confirm our findings
of acetazolamide-induced vasoconstriction, these experiments should be performed
with acetazolamide in combination of purinergic blockade. These outcomes could
further support our findings of reactive astrogliosis in the brainstem as pathological.
Consistent with our earlier data, we find that elimination of apneas prevents
further cognitive decline, suggesting a correlation between apneas and cognitive
outcomes. We must acknowledge the possibility that acetazolamide enhanced
respiratory activity while independently improving cognitive function by a different
and distinct mechanism. Intralateral ventricular administration of carbonic anhydrase
inhibitors enhanced synaptic efficacy and improved spatial learning/memory in rats.
(157) At the moment this model does not allow for the delineation of the two. The
inducible RTN specific GPR4 knockout model described previously could be of use
to further our understanding of this matter. The GPR4 knockout model presents with
a greatly diminished CO2/H+ sensing capacity of RTN neurons, therefore
Acetazolamide mediated increase of H+ should not induce a large alteration in
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respiratory activity. If this model of disordered breathing results in cognitive decline,
Acetazolamide therapy could also be initiated to understand the direct effects of the
drug on cognitive performance. Models of intermittent hypoxia would fail to answer
this question as Acetazolamide therapy stimulates respiratory activity in an attempt
to improve oxygenation, adverting hippocampal cell stress/loss.
Collectively, our findings indicate that 1.) MCAO induces respiratory
dysfunction possibly by disrupting astrocyte control of vascular tone in key brainstem
regions. 2.) The severity of respiratory instability, namely apneas, correlates with
progressive cognitive decline following MCAO. 3.) Improving respiratory activity by
suppressing apneas, as seen with Acetazolamide administration, prevents further
post stroke cognitive decline.
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Chapter 7. Conclusion.
The first report of stroke disrupting respiratory function originated in the early
1960s from the studies of Brown and Plum. (158) Since then numerous studies have
described a high prevalence of sleep disordered breathing following stroke.
Disordered breathing that accompanies stroke is associated with higher one-year
mortality and worse functional outcomes at the time of discharge, 3 months and 12
months following stroke. (17, 18) Importantly, a decrease in cognitive performance
was closely associated with the severity of respiratory disturbance, and an increase
in daytime sleepiness after stroke was a strong predictor of cognitive decline. (19)
Numerous experimental studies have been undertaken to comprehend the
effects of obstructive sleep apnea and/or intermittent hypoxia on the maladaptive
consequences of hypertension, heart failure and cognitive impairment. Our review of
the literature discovered only one experimental report of stroke altering ventilatory
patterns. Koo et al. reported that following transient 60-minute left middle cerebral
artery occlusion, A/J mice displayed an increase in the coefficients of variation for
respiratory frequency, tidal volume and minute ventilation 24 hours after stroke.
They concluded that ischemic stroke could develop a characteristic-breathing
pattern similar to Cheyne-Stokes respiration. (159) Albeit a significant finding, this
work did not fully characterize the respiratory phenotype induced by MCAO and
lacked any discussion of apnea, the fundamental feature of stroke disordered
breathing and a major contributor to hypoxia and cognitive decline. Advanced
chronological age is the most important non-modifiable risk factor for stroke and is
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an independent predictor of poor outcome after stroke. To date no studies have
been undertaken to investigate either age or sex as a biological variable in the study
of stroke induced respiratory dysfunction.
A large body of evidence exists suggesting that obstructive sleep apnea
increases the risk of declining neurological function, cardiovascular disease, cancer
and death. A majority of these studies employ intermittent hypoxia as a model to
mimic the episodes of apnea observed in sleep apnea. Potential mechanisms
contribute

to

cognitive

decline

include

neuro-inflammation,

mitochondrial

dysfunction, oxidative stress and neuronal apoptosis. (160) In the models of
intermittent hypoxia, investigators subjected animals to severe hypoxic conditions
resulting in arterial oxygen levels that plummeted to levels between 40-48 mmHg.
(161) These levels of PaO2 are extreme and far from measureable levels in human
studies of OSA (88.14±17.83 mmHg). (162) Our studies found mice suffering from
SIRD present with PaO2 levels of 79.3 and SpO2 desaturations to 90%, consistent
with human reports.
On the other end of the spectrum many studies report a neuroprotective effect
of intermittent hypoxia. Several animal models of neurological disease or injury,
including Alzheimer’s, brain and spinal cord injury have shown benefits of hypoxic
conditioning on enhancing neuroplasticity, cerebral vascular function and preventing
further cognitive decline. (163-165) Furthermore, the concept of rapid and delayed
post-conditioning induced neuroprotection, is proposed to minimize reperfusion
injury following a cerebral ischemic event by engaging the brain’s own endogenous
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responses. (166) This raises a critical question of whether stroke induced alterations
in respiratory activity serve as a compensatory response to improve outcomes, a
question that this study answers.
This study reports similar findings of Koo et al. in that 60 minutes of MCAO
produces alterations of respiratory activity in a separate mouse strain, C57B6. Koo
et al. reported alterations in respiratory frequency and minute ventilation 24 hours
after ischemia. Our findings indicate that these respiratory parameters are
continuously perturbed 3 and 7 days following ischemia. A key finding of this work
was that apneas are the underlying cause of respiratory instability. These episodes
of apnea not only decrease breaths per minute and subsequently minute ventilation,
but also result in periods of oxygen desaturation and systemic hypoxia. After fully
characterizing the respiratory phenotype resulting from following stroke, we sought
to understand if apneas are a consequence or compensatory response to ischemia.
We found that the number of apneic events an animal suffered per a minute
correlated with worse cognitive outcomes over a 42 day period. Consistent with
evidence from human stroke patients, a higher apnea-hypopnea index (AHI) directly
correlates with a decline in cognitive function.
Continuous positive airway pressure (CPAP) is a well-established therapy for
the treatment of obstructive sleep apnea and is currently the only treatment for
stroke disordered breathing despite its poor efficacy in these patients. Utilizing
knowledge of the molecular mechanisms contributing to neuronal respiratory activity,
we utilized the carbonic anhydrase inhibitor, Acetazolamide, to stimulate respiration.
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Which resulted in the elimination of apneas and ultimately improved long-term
cognitive

outcomes

following

stroke.

This

study

also

demonstrates

that

Acetazolamide differentially modifies vascular reactivity in the brainstem, offering an
alternative mechanism of stabilizing post stroke respiratory activity. The next line of
experiments conducted should aim to further clarify the mechanism(s) of
Acetazolamide stabilizing respiratory activity.
Lastly, this work provided insight into how stroke may disrupt respiratory
activity resulting in apneas. We discovered a pronounced astrogliosis surrounding
two key brainstem respiratory neuronal populations; the NTS and RTN.
Intracerebrovascular administration of TGF-β induced brainstem astrogliosis as well
as respiratory dysfunction and apneas. Suggesting a possible causative role of TGFβ mediated astrogliosis disrupting respiration. Further studies using astrocyte
specific TGF-β receptor knockout mice will further our understanding of respiratory
dysfunction stemming form TGF- β mediated astrogliosis and may help in the design
of efficacious therapies to prevent the development of SIRD.
This work was the first to fully characterize stroke induced respiratory
dysfunction and show that it is a maladaptive response resulting in progressive
cognitive decline. Although this work highlights the correlation between apnea
induced hypoxia and cognitive decline, further work is necessary. As previously
discussed in Chapter 4, the use of inducible RTN specific GPR4 knockout model can
further confirm a causal role of apneas leading to cognitive decline, while also
providing a model to study the underlying mechanism(s). This proposed work would
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have significant relevance beyond the field of stroke. Recently the Alzheimer’s
Association released a statement summarizing the findings of 3 separate studies
concluding that sleep disordered breathing is associated with an increase in amyloid
deposition, suggesting that SDB is an independent risk factor for Alzheimer’s. This
raises the possibility that interventions targeted to improving respiratory activity may
reduce the risk of Alzheimer’s. Interestingly, overproduction of TGF- β, astrogliosis
and

basement

membrane

thickening

enhanced

Alzheimer’s

disease

and

cerebrovascular abnormalities. (167) Furthermore, increased levels of TGF-B lead to
a decline in cerebrovascular dilatory ability and perturbed resting vessel tone in the
same animal model. (168)
This work recapitulated the findings of numerous studies reporting a negative
correlation between the incidence of apnea and cognitive function. Further
emphasizing this point, we found that elimination of apneas following Acetazolamide
therapy prevents further cognitive decline, strengthening the correlation between
apneas and cognitive outcomes. This work has established a murine model of stroke
induced respiratory dysfunction. Laying the groundwork for further investigations into
the mechanisms of disordered breathing and the development of therapies to
prevent respiratory dysfunction and ultimately cognitive decline. Ameliorating
respiratory instability and sequelae is of high relevance to several disciplines in
preventing cardiovascular disease, stroke, cancer and death, improving overall
patient health and wellbeing.
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